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1. INTRODUCTION 
 
Allergic diseases are the most frequent chronic diseases in childhood [1] and one 
important manifestation is asthma. This pulmonary disease presents with airway 
hyperresponsiveness leading to airway obstruction and shortness of breath. 
Patients suffer from acute respiratory distress with expiratory wheeze that can lead to 
extreme anxiety, tachycardia and - if untreated - can result in the life-threatening status 
asthmaticus [2].  
Although its pathogenesis is not completely understood, many factors contributing to the 
development of asthma have been found including environmental exposure [3], nutrition 
[4], genetic and epigenetic mechanisms [5].   
World-wide, an estimate of 334 million people are affected by this disease with the 
prevalence in children having increased over the past decades up to 14 percent [6]. As 
asthma comes along with the potential threat of exacerbations and a life-long need for 
treatment, especially an early onset of the disease – childhood asthma – puts a burden on 
both the little patients with their families and the public health care system. 
Many approaches have been established in order to control asthma symptoms and to 
prevent exacerbations. However, over the past decades it became clear that asthma is 
rather a clinical syndrome than a ‘simple’ disease, paying tribute to its many different 
manifestation forms. 
In early life, asthma cannot be diagnosed due to the limited compliance of young children. 
Therefore, the term `wheeze´ was established for young patients with asthma-like 
symptoms. Childhood wheeze is known to be a crucial risk factor for asthma development 
[7].  However, research is recently focusing on the heterogeneity of childhood wheeze 
and the different outcomes later in life. While some children develop asthma, others are 
likely to outgrow their symptoms [8]. 
In this context, the need for a more individual therapy has increased, leading to the 
necessity of a more precise classification of affected patients. Therefore, defining 
different phenotypes and finding potential biomarkers has become of recent interest.   
 
1.1. Asthma classification 
1.1.1. Phenotyping wheezing infants  
Many approaches for classifying childhood asthma have been established. To date, one 
common classification is dividing children into either allergic or non-allergic asthma type. 
Whereas allergic asthma is characterized mainly by specific sensitization and high IgE-
levels, non-allergic asthma features neutrophilic inflammation [9].  
Due to the limited compliance in lung function testing especially of younger children, the 
definitive diagnosis ‘asthma’ cannot be made before the age of 5 years, leaving a 
classification gap for younger children with asthma-like symptoms. Therefore, so-called 
wheeze phenotypes have been described for preschool-age children. These infant wheeze 
phenotypes are defined by two approaches: by a clinical and an epidemiological 
perspective.  
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Clinical phenotyping is based upon criteria such as symptom triggers, their association 
with infections, patient history and allergic sensitization as well as with frequency and 
severity of symptoms. Considering all those clinical features, the resulting phenotypes 
mainly focus on what the symptoms are triggered by, how patients respond to treatment 
and what other allergic symptoms they have [10]. These phenotypes include, for 
example, multitrigger wheezing, unremitting, frequent or episodic wheezing.  
An additional clinical approach is driven by the predominant cell type found in patient 
samples, like peripheral blood samples or bronchoalveolar lavage fluid resulting in an 
eosinophilic phenotype (with mainly TH2 cells and eosinophilic granulocytes) and a 
neutrophilic phenotype (with mainly TH1/TH17 cells and neutrophilic granulocytes). 
In contrast, epidemiological considerations focus on variation with time and are driven 
by data-based latent class analysis. This analysis is part of the structural equation 
modeling that identifies subgroups of cases in multivariant categorical data. In asthma 
research, this leads to phenotype definition such as early transient, persistent and late-
onset wheezing [11].  
Those two approaches have been compared lately, showing that they are highly correlated 
and that clinical phenotyping is well supported by epidemiological phenotyping [12]. 
When trying to define different phenotypes, differentiation between endotypes has 
become more and more important.    
 
1.1.2. Endotyping childhood wheeze 
The term endotyping describes the approach to define different subgroups of a disease, in 
this case wheezing infants, according to molecular mechanisms contributing to its 
pathogenesis. Gaining a better understanding of the molecular mechanisms leading to 
childhood wheeze - and the potential development of asthma later in life - might be a way 
to provide a more personalized and therefore more effective treatment strategy. This could 
help especially those patients who do not respond well to today’s treatment guidelines. 
With our current knowledge we are not satisfactorily able to explain those treatment 
failures and the reasons why they fail, suggesting that the complexity of asthma and the 
resulting patients’ heterogeneity need further investigation from a new perspective. 
To classify endotypes, information from molecular pathways is put together: genome-
wide association studies tried to find single nucleotide polymorphisms correlated with 
asthma risk and protection [13], gene expression on RNA level has been investigated 
along with its regulation by micro RNA [14] and protein levels have been studied by 
looking at differences in cytokine levels in asthmatic patients and healthy controls. All 
these efforts result in new insights into the disease’s pathology and may help to find new 
promising therapeutic targets. 
In this project, focus has been put on identifying potential new genes of the innate immune 
system associated with an increased risk for asthma at the earliest possible time point, 
directly after birth. The analysis at said time point might contribute to finding potential 
new biomarkers for the prediction of subsequent asthma development.  
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1.2. Immune system 
1.2.1. Innate immune system 
Every day, our immune system has to face an enormous number of antigens resulting in 
the need of providing a very quick ‘first-line’ response to potential harming 
microorganisms.  
In order to ensure a rapid response, the human body has brought up a wide range of cells 
that quickly but unspecifically fight potential threats like pathogens, necrotic and 
apoptotic cells or tumor cells: the innate immune system. 
This initial immune response is highly conserved over evolution and is provided by 
monocytes/macrophages, dendritic cells, natural killer cells, eosinophil, basophil and 
neutrophil granulocytes and mast cells, with each cell type having a specific function 
within the immune system (see Figure 1). 
 
Figure 1: Cells of the innate immune system.         
 Phagocytosis= engulfing of a solid particle into an intracellular vesicle called phagosome followed by an   
         enzymal digestion        
Chemotaxis= cell movement in response to chemical stimuli like cytokines    
 Cell functions taken from Lüllmann-Rauch [15] 
 
In order to fulfill their function, it is essential that the cells of the innate immune system 
are able to distinguish between ‘foreign’ cells and natural body components. For that 
determination so-called pathogen-associated molecular patterns (PAMPs) play a crucial 
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role. PAMPs are highly pathogen-specific target for innate immune cells as they are only 
produced by microorganisms, invariant between those of a given class and essential for 
microbial survival [16]. 
The recognition of PAMPs is provided by the pattern recognition receptors (PRRs) that 
play a major role in shaping the innate immune response. 
Additionally, the innate immune system senses cell damage like necrosis with the help of 
damage-associated molecular patterns (DAMPs). Those molecular patterns are mainly 
formed by intracellular molecules like RNA or S100 proteins with their extracellular 
appearance signalling cell lysis. 
When identifying PAMPs or DAMPs, cells of the innate immune system, especially 
macrophages and neutrophilic granulocytes, rapidly trigger a pro-inflammatory immune 
response leading to the liberation of various cytokines like Interleukin-1, Interleukin 8, 
tumor-necrosis factor α (TNFα) and Interferon γ (IFNγ). 
Another important function of the innate immune system beside the ‘first-line’ response 
is the presentation of antigens on major histocompability complexes (MHCs). Especially 
the phagocytes, including dendritic cells, macrophages and neutrophil granulocytes, 
fulfill this function leading to the recognition of the invaded pathogen by the adaptive 
immune system. 
Although the innate immune system is essential for the human immunity, an aberrant 
activation and dysregulation can result in inflammatory and atopic diseases [17-19]. 
It has been shown that some cell types of the innate immune system, especially 
neutrophils and eosinophils are enriched in children with asthma[20] highlighting the 
potential role of those cell types in asthma manifestation. 
Furthermore, Boeck et al. found differently expressed innate immune pathways in 
different childhood asthma phenotypes  [21]. 
Asthma might also be combined with the reduced ability to fight a systemic virus 
infection caused by an inadequate response by the innate immune system [22]. 
While the important impact of the adaptive immune system on asthma has already been 
shown, the question arises by what mechanisms this adaptive immune response is 
modulated [23-25]. Therefore, recent research has put focus on the impact of the innate 
immune system [26]. 
Dendritic cells play a major role in antigen presentation and triggering of the adaptive 
immune response by priming of naïve T cells. This priming step is crucial for the 
development of either a TH1 or TH2 cell response resulting in different cytokine milieus 
that have an impact on the development of asthma. Only mature dendritic cells are able 
to stimulate naïve T cells. As the shift of naïve T cells towards either TH1 or TH2 cell 
response is essential for asthma development and mediated by mature dendritic cells, the 
maturation process of the dendritic cells has to be tightly regulated. Dendritic cell 
maturation is shaped by the innate immune system resulting in a crucial role of the innate 
immune system in asthma pathology [24].  
In order to further understand this expected role, genes associated with toll-like receptors, 
RIG-I like receptors, C-type lectin receptors, the immunoproteasome and the 
inflammasome – that all shape the innate immune response – were analyzed in this 
project.  
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1.2.2. Adaptive immune system 
Following the rapid initial immune response provided by the innate immune system, the 
adaptive immune system raises a more target-orientated and therefore specific immune 
response. However, this response takes 4-7 days to be established [27]. 
Additionally, the adaptive immune response has a memory function. 
Upon activation and priming, two cell types mediate adaptive immunity: B cells and T 
cells, with their different subtypes that can be differentiated by their specific cell surface 
molecules, the so-called cluster of differentiation (CD) antigens and their function (see 
Figure 2).  
Naïve B cells mature into plasma cells, that repel pathogens by releasing specific 
immunoglobulins (Ig), the so-called antibodies and into said memory cells which provide 
a quicker response in case of a new infestation by the same pathogen. 
T cells form the T effector cells that recognize and kill infected cells and T helper cells 
and regulatory T cells that shape and modulate the immune response. 
 
 
Figure 2: T and B cell differentiation.  
Modulated by dendritic cells, naïve CD4+ Tcells (Cluster of Differentiation 4) differentiate to various subtypes of 
THelper (TH) cells that secrete cell specific Interleukins (IL), Interferon-y (INFγ). Additionally they can turn into 
regulatory T cells (Treg) that produce among others transforming growth factor β (TGFβ). Naïve CD8+ T cells mature 
into cytotoxic T lymphocytes (CTL) producing various cytotoxins in order to kill infected cells. Naïve B cells can turn 
either into immunologically active plasma cells producing immunoglobulins (Ig) or to a small amount into memory B 
cells providing a quicker response to reinfection by a known pathogen. Figure adapted from Klucker, Raedler [28]. 
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Various studies have already linked the specific subtypes of adaptive immune cells to 
different asthma manifestations, highlighting the important role of TH1/TH17 [29], TH2 
[18] and Treg [9, 30, 31]in the pathogenesis of childhood asthma. 
Over the past decades, asthma has been seen as mainly a TH2 disorder [25] with the 
imbalance between TH2 and TH1 cells contributing to the asthma development. Recently, 
there has been growing evidence that not only TH2 cells but also other T cell subtypes 
like TH17 cells and Tregs have a crucial impact on the disease’s pathology. For example, 
it has been shown that the acetylation of Treg genes differ between children with an asthma 
risk and healthy controls [32]. 
 
1.3. NFkB signalling and gene regulation 
 
The nuclear factor 'kappa-light-chain-enhancer' of activated B-cells -signalling pathway 
(NFĸB signalling pathway), expressed in almost all mammalian cell types [33], is known 
to play a crucial role in the development of inflammation, modulation of the innate 
immune response and in the pathology of asthma [34].  
The protein complex consists of NFĸB1 (p105/p50), NFĸB2 (p100/p52), RelA (p65), 
RelB and c-Rel [35]. They all have an N-terminal Rel homology domain (RHD) that 
enables them to sequence-specifically bind DNA. 
Upon activation, the subunits of the NFĸB complex form diverse homo- and hetero-
dimers that transfer to the nucleus and lead to the transcription of pro-inflammatory 
signalling pathway genes. 
In the unstimulated cell, the NFĸB complex is inhibited by its antagonist, the IĸBs 
(Inhibition of kappa B) that bind to the RHD and retain the NFĸB dimers in the cytoplasm.  
Cell stimulation leads to the activation of the IκBα kinase complex (IKK) that liberates 
the NFĸB subunits by phosphorylation and degradation of the IĸBs. 
Three proteins belong to the IKKs: IKKα, IKKβ and IKKγ/nemo.  
There are two different pathways of NFĸB stimulation: the classical or canonical pathway 
and the alternative pathway (see Figure 3). 
Many pro-inflammatory cytokines and PAMPs activate the classical pathway by binding 
to tumor necrosis factor (TNF) receptors and Toll-like receptors (TLR). The classical 
pathway is then mainly mediated by the IKKβ/γ leading to the liberation and dimerization 
of RelA:p50 and c-Rel:p50 dimers and plays a crucial role in the innate immune system 
[36]. 
In the alternative pathway, a small subset of TNF family members activate IKKα via the 
NFĸB inducing kinase [37]. The alternative pathway seems to play a role in modulating 
the adaptive immune response as it has an impact on the spleen development and 
organization [36]. 
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Figure 3: Canonical (left) and alternative (right) pathway of NFĸB activation. In the canonical pathway, through 
activation of various receptors, the IKK (IκBα kinase complex) is activated and phosphorylates IĸB (inhibitor of NFĸB). 
This leads to the ubiquitination and degradation of IĸB resulting in the liberation and dimerization of the NFĸB subunits 
which then transfer to the nucleus and induce gene expression. The alternative pathway is mediated through the 
activation of NIK (NFĸB inducing kinase), also resulting in the dimerization of NFĸB subunits and is induced by a 
small number of TNF family member. Figure by Gerondakis, Fulford [38] 
By now, not all details of the NFĸB signalling pathway are fully understood. However, 
various studies highlight its important role in the regulation and modulation of the 
immune system. Additionally, research has focused on the NFĸB dysregulation in 
autoimmunity and inflammatory diseases such as asthma [39] leading to further 
understanding of the known therapeutic effect of NFĸB inhibition [40].  
Furthermore, it has been shown that a protective effect on asthma development is 
mediated through the limitation of NFĸB pathway activity by A20 [41, 42]. These 
findings indicate that the dysregulation of NFĸB associated pathways contribute to the 
pathology of asthma.  
Therefore, it seems highly interesting to further investigate what causes the dysregulation 
that may contribute to the development of asthma. In this project, genes that both 
influence the NFĸB signalling pathway and are partly already linked to asthma 
development were analyzed in cord blood cells to investigate whether their expression 
differs from healthy children already in the very beginning of life. 
 
1.4. Genes of interest 
1.4.1. Toll-like receptors 
The toll-like receptor (TLR) family is a large group of the so-called pattern recognition 
receptors (PRR) and consists of 10 known TLRs in humans (TLR1-10) expressed mainly 
on antigen presenting cells. 
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TLRs play a crucial role in the recognition of PAMPs, the initiation of the innate immune 
response and the orchestration of the following adaptive immune response [16, 43].  
Upon stimulation, TLRs use a wide range of signalling pathways to activate cells of both 
the innate and adaptive immune system (see Figure 4). Those pathways can be divided 
into receptor-specific and shared pathways. One pathway that seems to be shared by all 
TLRs is the activation of NFĸB as demonstrated in Figure 4. 
 
 
Figure 4: TLR signalling pathway. Upon activation, TLRs trigger an immediate immune response by, among other 
things, the activation of the NFĸB signalling pathway via IRAK and TRAF6. Figure by O'Neill, Golenbock [44] 
Some TLRs, like TLR4 and TLR2 have already been linked to the development of atopic 
diseases [45-47]. However, the role of other TLRs like TLR5 and TLR7 in the disease 
pathogenesis is not fully understood and of growing interest [48]. Table 1 shows the 
analyzed TLRs in this project. 
 
Table 1: Genes of interest of the Toll-like receptor family 
Gene Name Location and function Relevance for this project 
TLR5 Toll-like 
receptor 5 
Cell membrane receptor for 
the recognition of lipid 
structures and flagellin  
• TLR5 expression has shown to be 
downregulated in lymphocytes of 
asthmatic patients [49] 
• Flagellin has been shown to play a role 
in the sensitization to indoor allergens 
priming allergic asthma [50] 
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1.4.2. RIG-I like receptors 
Another group of PRRs of growing interest are the so-called retinoic acid-inducible gene 
I (RIG-I) –like receptors (RLRs). RLRs have just recently become the focus of 
investigation and therefore their role in the immune system remains yet to be fully 
understood.  
This family consists of three receptors: RIG-I, melanoma differentiation associated gene-
5 (MDA-5) and laboratory of genetics and physiology 2 (LGP2) that all sense viral 
double-stranded RNA [52]. 
They all contain a DExD/H RNA helicase domain along with two caspase activation and 
recruitment (CARD) domains (LGP2 has only one card domain) and are located in the 
cytoplasm. Additionally, RIG-I contains a repressor domain. RLR signalling leads to the 
activation of MAP kinase, IRF and NFĸB pathway [53]. Therefore, the following genes 
of this pathway were investigated. 
 
Table 2: Genes of interest of the RIG-I like receptor family 
Gene Name Location and function Relevance for this project 
RIG-I 
(DDX58) 
Retinoic acid-
inducible gene I 
Intracellular receptor for the  
recognition of viral RNA,  
specifically (ds)RNA 
• Key regulator of innate immune 
response [52] 
MDA-5 
(IFIH1) 
Melanoma 
differentiation 
associated gene-
5 
Intracellular receptor for the  
recognition of viral RNA,  
specifically (ds)RNA 
 
• Key regulator of innate immune 
response [52] 
• Plays a role in the initiation of 
airway inflammation after 
rhinovirus infection in mice [54]  
 
1.4.3. C-type lectin receptors 
A third group of PRRs is formed by the C-type lectin receptors (CLRs) which recognize 
carbohydrate ligands. CLRs are expressed on almost all cell types and can be divided into 
17 groups based on their different characteristics [55].Shared pattern of this group are the 
calcium dependent function, a stalk region, a transmembrane region, a signal transduction 
region and an extracellular carbohydrate recognition domain (CRD). Based on their CRD 
they can be divided into two groups: the Dectin-1 cluster with just an extracellular CRD 
and the Dectin-2 cluster with an additional cytoplasmic CRD [55]. 
TLR7 Toll-like 
receptor 7 
Intracellular receptor of the 
endosomal membrane 
Recognizes the nucleic acids 
of both virus and bacteria, 
specifically the (ss)RNA 
 
• TLR7/8 are potential risk genes for the 
development of asthma and other atopic 
diseases [51] 
• Adolescents with asthma show a 
reduced TLR 7 function [22] 
• Stronger TLR7/8 response was 
identified in PBMCs of children with 
non-infectious asthma exacerbation 
[47] 
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Upon stimulation, the CLRs trigger an activation of the NFĸB signalling pathway (see 
Figure 5). Therefore, CLRs have an impact on shaping the innate immune response [55], 
the initiation of airway inflammation [56] and might play a role in the development of 
allergic diseases. 
 
 
Figure 5: CLR signalling pathway. Stimulation of the CLRs leads to either a direct signal (DC-SIGN, Dectin1) or an 
indirect signal vial FcRγ chain (Dectin2, Mincle) resulting in the activation of NFĸB and NLRP3 inflammasome. Figure 
adapted from Romani [57] 
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Table 3:  Genes of interest of the CLR family 
Gene Name Location and function Relevance for this project 
Mincle 
(CLEC4E) 
C-type lectin  
domain family  
4 member E 
Cell membrane receptor that 
recognizes DAMPs and cord factor, 
a component of the cell wall of 
Mycobacterium tuberculosis    
• Mincle induces IL-1 and 
IL-6 leading to the 
development of a TH1 
and TH17 phenotype in 
human and mice [58] 
Dectin1 
(CLEC7A) 
C-type lectin  
domain family  
7 member A 
Cell membrane receptor for the  
recognition of glucans of fungi,  
bacteria and plants 
• Modulates NFĸB 
signalling pathway [55]  
• Has an impact on the 
development of non-
atopic asthma associated 
with damp buildings [59] 
• Plays a role in house dust 
mite induced allergic 
airway inflammation in 
mice [60]  
Dectin2 
(CLEC6A) 
C-type lectin  
domain family  
6 member A 
Cell membrane receptor for 
numerous endogenous and 
exogenous ligands 
• Plays a role in sensing of 
house dust mite and the 
following aberrant 
airway inflammation [56] 
• CLRs might play a role in 
the development of 
allergic asthma [61] 
 
1.4.4. Immunoproteasome 
In unstimulated cells, the standard proteasome consisting of the constitutively active β1, 
β2 and β5 subunits is expressed and forms a cytosolic protein complex that cleaves 
ubiquitinated proteins into small fragments which are then presented by the major 
histocompatibility complex I (MHC I). The presentation on MHC I enables the activation 
of innate immune cells, especially the natural killer cells.  
Upon activation by inflammatory signals, there’s a shift in the gene expression leading to 
the production of different proteasomal subunits, the so-called i-units (β1i, β2i and β5i). 
These subunits form a special type of proteasome, the immunoproteasome.  
Immunoproteasomes are more active than the standard proteasomes and provide slightly 
different peptide fragments [62]. Additionally, they shape the T cell immune response as 
they have been reported to play a role in the T cell expansion [63]. The impact of the 
immunoproteasome on NFĸB signalling is discussed controversially with recent evidence 
for its important modulating role [64].  
 
Table 4:  Genes of interest of the immunoproteasome 
Gene Name Location and function Relevance for this project 
LMP2 Low molecular 
mass 
polypeptide 2 
Forms the β1i subunit of the 
cytosolic immunoproteasome 
• The immunoproteasome might have a 
major impact on the NFĸB signalling 
pathway [64] 
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LMP7 Low molecular 
mass 
polypeptide 7 
 
Forms the β5i subunit of the 
cytosolic immunoproteasome 
• Patients with a LMP7-mutation have 
lower immunoproteasome content and 
show a spectrum of auto-inflammatory 
diseases that implicate aberrant NFĸB 
signalling [64]  
• LMP7 deficiency and inhibition 
suppresses Th1 and Th17 but enhances 
Treg differentiation [65] 
 
1.4.5. Inflammasome and Interleukin-1 receptor I 
The inflammasome is a group of cytosolic protein complexes composed of nod-like 
receptor (NLR) proteins –a PRR subfamily–, an apoptosis-associated speck-like protein 
containing a CARD (ASC) domain and caspase-1. These components form different 
subfamilies, with different molecular structures, of inflammasomes like the AIM2, the 
NLRP1, the NLRC4 and the NLRP3 inflammasome. The inflammasome senses a wide 
range of stimuli, like PAMPs and DAMPs and by modulating the caspase-1 activity 
coordinates the subsequent cell response [66]. Caspase-1 cleaves the inactive Interleukin-
1β (IL-1β) and IL-18 pro-forms into active cytokines that are known to play a crucial role 
in triggering pro-inflammatory signalling pathways [67, 68] and the regulation of TH cells 
[69]. Both cytokines are also induced by the NFĸB pathway, providing a link between 
inflammasomal and NFĸB signalling.  
 
 
Figure 6: NLRP3 signalling pathway. Upon activation by PAMPs and DAMPS the NLRP3 inflammasome 
oligomerizes leading to the auto-activation of caspase-1. Figure by Tschopp and Schroder [70]. 
Among this family, the NLRP3 inflammasome has become of special interest as there is 
growing evidence for its role in airway inflammation [68, 71].  
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The cell-membrane receptor Interleukin-1 receptor type I (IL-1R1) is activated by IL-1α 
and IL-1β and further mediates the signal. In contrast,  IL-1R2 attenuates the IL-1α and 
IL-1β signal.  
Therefore, the expression of following genes was determined. 
 Table 5: Genes of interest of the NLRP3 inflammasome and IL-1R1 axis 
 
1.4.6. Overview of the analyzed signalling pathways 
Gene Name Location and function Relevance for this project 
NLRP3 NOD-like 
receptor family, 
pyrin domain 
containing 3 
Protein of the cytosolic NLRP3 
inflammasome, that upon PAMP and 
DAMP sensing modulates the innate 
immune response by activating 
caspase-1  
• Modulates airway 
inflammation [68] 
• elevated in patients with 
neutrophilic asthma [71] 
CASP1 Caspase-1 Intracellular enzyme that cleaves the 
immature pre-IL-1β and pre-IL18 into 
biologically active cytokines 
• IL-1β and IL-18 play a crucial 
role in asthma development 
[67, 68] 
IL-1R1 Interleukin-1 
receptor type I 
Cell membrane receptor for IL-1α and 
IL-1β 
• Contributes to the 
development of HDM-related 
asthma in murine model [72] 
• Has been associated with 
severe asthma in humans [73] 
Figure 7: scheme of analyzed signalling pathways, simplified  
Figure designed with motifolio.com 
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2. AIM OF THIS PROJECT 
Over the past decades, it became clear that asthma is a much more heterogeneous disease 
than assumed leading to the need of a more specific classification of patients.  
Even though some factors contributing to the early onset of this disease like 
environmental factors, nutrition and smoke exposure have been discovered, many 
questions about the genetic and epigenetic influence remain to be clarified. 
Many approaches have been established in order to provide said classification.  
In this context analysis of variation in the expression of defined genes – acting as potential 
new biomarkers – can contribute to a more detailed classification. 
One promising approach when trying to define potential candidate genes is looking into 
the disease’s molecular pathomechanism as affected children are likely to express genes, 
especially ones related to asthma development, differently from healthy children.  One 
important pathomechanism is the chronic airway inflammation signs of which can also 
be detected in peripheral blood. 
Inflammatory processes play a key role in the development of asthma as their 
dysregulation leads to the imbalance of cytokines contributing to the pathogenesis of 
asthma.  
The innate immune system plays a crucial role in asthma development by triggering those 
inflammatory signals and shaping the adaptive immune response. Among others, the 
inflammatory signals are mediated by Toll-like receptors, C-type lectin receptors, RIG-I 
like receptors, the inflammasome and the immunoproteasome which makes the genes 
expressing these proteins interesting candidates for such novel biomarkers. 
As it would be of great interest for therapeutic and preventive measures to detect hints 
predicting an onset of asthma at an early point in life, the analysis of cord blood samples 
seems to be promising. Not only is it easily available straight after child birth, collection 
of cord blood is also a non-invasive method of obtaining samples. 
 
Therefore, the following hypotheses were tested in this project: 
(1) We hypothesized that the gene expression of genes related to signalling pathways 
of the innate immune system increases significantly after PHA or LpA stimulation 
of cord blood mononuclear cells. 
 
(2) We aimed to detect differences in the expression of said genes between the 
different wheeze-subtypes. 
 
(3) We hypothesized that the regulation of these genes differs between the different 
wheeze phenotypes and healthy controls. 
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Reagents and chemicals  
 
100bp DNA ladder (500μg/ml) New England BioLabs, Ipswich, USA 
Boric acid Sigma-Aldrich, Steinheim, Germany 
Bromphenol blue Roth, Karlsruhe, Germany 
EDTA Sigma-Aldrich, Steinheim, Germany 
Ethanol 100% Merck, Darmstadt, Germany 
Ethidiumbromide (10mg/ml) Biorad, Hercules, USA 
Glycerol Sigma-Aldrich, Steinheim,Germany 
H2O bidest. H. Kerndl GmbH, Weißenfeld, Germany 
Primers  Life technologies, Invitrogen, Carlsbad, USA 
Trizma Base Sigma-Aldrich, Steinheim, Germany 
Water DEPC (0.1 %)  Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Xylene cyanol                                                Merck, Darmstadt, Germany  
 
3.1.2. Solutions and buffers 
 
5X TBE buffer  
 
54g trizma base  
27.5g boric acid 
20ml 0.5M EDTA (pH 8.0) 
Ad 1l H2O bidest. 
DNA ladder 
 
10μl 100bp DNA ladder  
80μl 0.5x TBE-Buffer 
10μl loading dye diluent  
Ethidiumbromide [500μg/ml]  
 
100μl ethidiumbromide 
1.9 ml H20 
Loading dye stock solution 0.25g bromphenol blue 
0.25g xylene cyanol 
30% glycerol 
70ml dH2O 
Loading dye diluted solution 5ml loading dye stock solution 
13.5ml glycerol 
31.5ml dH2O 
 
3.1.3. Reagent systems (Kits) 
 
Sso advanced SYBR green Supermix Biorad, Hercules, USA 
QuantiTect Reverse Transcription Kit  Qiagen, Hilden, Germany  
 
3.1.4. Consumables 
 
96-Well White Shell PCR Plates  BD Biosciences, Heidelberg, Germany  
Microseal® ‘B’ seal seals Biorad, Hercules, USA 
Biosphere® filter tips 10μl M 40mm type D  Sarstedt, Nümbrecht, Germany  
Biosphere® filter tips 100μl  Sarstedt, Nümbrecht, Germany  
SafeGuard Filter tips 100-1000μl  Peqlab, Erlangen, Germany  
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3.1.5. Laboratory equipment  
 
Centrifuge Perfect SpinP Peqlab, Erlangen, Germany 
Electrophoresis power supply VWR International, Radnor, USA 
Gel iX Imager Intas Science Images Instruments, Göttingen, 
Germany 
CFX96 TouchTM Real-time PCR Detection 
System 
Biorad, Hercules, USA 
 
3.1.6. Softwares 
 
Biorad CFX Manager 2.1 Biorad, Hercules, USA 
EndNote X9 ISI ResearchSoft, Berkeley, USA 
Ensembl Genome Browser http://www.ensembl.org/ 
National Center for Biotechnology 
Information 
http://www.ncbi.nlm.nih.gov/ 
R program Version 3.2.2. http://www.R-project.org/  
SPSS version 23 SPSS IBM Inc., Armong, USA 
Vector NTI 10 Advance 11.5  Invitrogen, Carlsbad, USA  
 
3.1.7. Primers  
 
Gene Forward sequence Reverse sequence 
TLR5 GTATTTCTGTGGTCTCTCTGATGCTG GCTGCGAGGCTAAAAAAGGAG 
TLR7 ATGCTGTGTGGTTTGTCTGGTG ATACCACACATCCCAGAAATAGAGG 
RIG-I GAAGAGAGCAGGATTTGTAAAGCCC CTGCTCGGACATTGCTGAAGAAG 
MDA-5 TTCCGAGAGAAGATGATGTATAAAGC GCAAAGGAAAGTTATTAGTGATGGG 
Mincle CTACTGACACCATTTCCTGGGCG TTGCCACTGACCCTCGACAACC 
Dectin1 GACTCTCAAAGCAATACCAGGATAGC TAATCTCCTCCACCAAATACTCACC 
Dectin2 TGGCAAAAGGCTGTCTGAACTAC GCCCCAGAAAATAAGAAAATGACTC 
LMP2 AGGCGAGGCGGTGGTGAA CCTTCACGTTGGTCCCAGCC 
LMP7 CCACCACGCTCGCCTTCAA TCCTGAGAGCCGAGTCCCATG 
NLRP3 AAAGCAAAAAGAGATGAGCCGAAG AGTCGTGTGTAGCGTTTGTTGAGG 
Casp1 CGCTTTCTGCTCTTCCACACC CGCTCTACCATCTGGCTGCTC 
IL1R1 GCATCCTACACATACTTGGGCAAG GTAATTGATGAAGATGACCCAGTGCT 
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 
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3.2. Study population 
3.2.1. PAULINA  
In the Pediatric Alliance for Unselected Longitudinal Investigation of Neonates for 
Allergies (PAULINA) study [74], cord blood samples from newborns of the Munich 
metropolitan area, Germany, were collected. Atopic and non-atopic mothers were 
recruited in the last trimester of pregnancy. 
The study has been approved by the Bavarian Ethical Board, LMU Munich, Germany. 
In collaboration with the delivery room nurses of the University gynecology hospital 
(Maistrasse, LMU) n=190 mothers were recruited between October 2004 and September 
2007. Inclusion criteria were an uncomplicated pregnancy and healthy neonates and 
exclusion criteria contained preterm delivery, perinatal infections, maternal use of 
antibiotics during the last trimester of pregnancy and chronic diseases of the mother. 
Two groups were recruited: neonates with an atopic mother and neonates with a non-
atopic mother. Maternal atopy was defined as having received a doctor’s diagnosis of 
asthma and/or allergic rhinitis and/or atopic dermatitis. 
Cord blood samples from the neonates along with blood samples from the mothers were 
collected. Sample processing was performed within 24h in our laboratory. 
Cord blood mononuclear cells (CBMCs) were isolated and exposed to different innate 
and adaptive immune response related stimuli and mitogens in order to find out whether 
the immune system of newborns from atopic mothers reacts different to those stimuli than 
newborns from non-atopic mothers. 
In maternal blood, total IgE along with specific IgE (Immunoblot assay) was measured. 
A positive specific IgE was defined as ≥0.35 IU/mL to one or more common allergens 
from a panel of 20 allergens including plants, animals, foods, latex and house dust mite.  
 
3.2.2. PAULCHEN 
In the PAULCHEN study (Prospective Cord Blood Study in Rural Southern Germany) 
[3], 91 pregnant mothers from rural southern Germany were recruited from September 
2005 to December 2008. 
Approval was obtained from the Bavarian Ethical Board, LMU Munich, Germany. 
In collaboration with the obstetric clinic (Asklepios Clinic) Bad Tölz, cord blood samples 
were collected and processed within 24h in our laboratory.  
Inclusion and exclusion criteria were equal to the PAULINA study (see above). 
In contrast to the PAULINA study, the following groups were defined: the farming group 
was defined as the mother having lived and/or worked on a farm during pregnancy 
whereas the non-farming group was defined as the mother having lived in rural 
environment during pregnancy. In order to increase the total sample size, a selected 
number of children from the PAULCHEN study was included in this project. Only non-
farming children were selected as they have no general protection from allergy and 
therefore are easily comparable with children from the PAULINA study. 
Sample material and work-flow were equal to the PAULINA study (see above).  
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3.2.3. Follow up 
At the age of 3 years as well as at the age of 6 years a follow-up study was performed. 
For this purpose, the parents completed a detailed questionnaire including information 
about both present and past symptoms. Special focus has been put on the follow up of 
wheeze symptoms, airway inflammation and allergy symptoms. The follow up was 
performed in both study cohorts and is still on-going at age of 10 years currently. 
Those data were used for the phenotype definition of the children.  
 
Table 6: comparison of PAULINA and PAULCHEN study 
 PAULINA PAULCHEN 
Focus Difference between the 
newborn’s immune 
responses to different 
stimuli in correlation with 
the mother’s atopy status 
Difference between the 
newborn’s immune 
responses to different stimuli 
in correlation with the 
mother’s farming status 
during pregnancy 
In this project only non-
farming children were 
included 
Recruitment time span  October 2004 –  
September 2007 
September 2005 –  
December 2008 
Total sample size n= 190 n=93 
Inclusion and 
exclusion criteria 
Inclusion: uncomplicated pregnancy and healthy neonate 
Exclusion: preterm delivery, perinatal infections, maternal 
use of antibiotics during the last trimester of pregnancy, 
chronic diseases of the mother 
Follow- up Age 3 years, age 6 years Age 3 years, age 6 years 
Blood sample collection, processing and stimulation was identical for both study 
populations allowing the joint data analysis performed in this project. 
 
3.3. Declaration of my contribution 
Due to the longitudinal character of the PAULINA/PAULCHEN studies, some of the 
laboratory work took place prior to this project. The recruitment of patients, from 2004 
to 2008, the cell stimulation directly following the blood withdrawal and the RNA 
extraction were performed by group members of the AG Schaub. 
As this project focused on finding potential new biomarkers for the prediction of 
childhood wheeze, I designed and selected the primers for this project, performed the 
synthesis of cDNA, the following quantitative real time PCR, gel electrophoresis and 
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the quality control. I also checked the data analysis myself and performed the basic 
statistical analysis. The more complex statistical analysis has been supervised.  
 
3.4. Blood withdrawal 
 
All participating families were informed about the study by a physician and gave their 
written consent. 
Blood withdrawal of the umbilical cord blood took place directly after delivery and was 
performed by a midwife or obstetrician. 30-40ml of blood were taken and treated with 
Liquemin for anticoagulation. Additionally, 1ml of blood was taken and stored in an 
EDTA tube at -80°C. 
Furthermore, 4.9 ml serum from the mother were obtained from a peripheral vein. 
 
3.4.1. Detection of maternal cells in the cord blood samples by 
karyotyping 
 
In order to ensure no relevant contamination of the cord blood cells with maternal cells, 
some male samples were tested for potential contamination. For this purpose, isolated 
CBMCs were incubated with Colcemid (Invitrogen, Karlsruhe), a microtubule-
depolymerizing drug, for 30 min. The resulting precipitate was centrifuged and 
resuspended in 0.54% potassium chloride and again incubated for 25min at 37°C. The 
cells were then fixed in methanol with the help of a 33% glacial acetic acid solution and 
put on slides.  
The X and Y chromosomes were stained with a dichromatic alpha-Satellite Kit (Rainbow 
Scientific, Banbury, UK), thus allowing differentiation between maternal cells with a XX 
karyotype and fetal cells with a male XY karyotype.  
There was no relevant contamination of maternal cells detected in the CBMCs. This 
experiment took place in the beginning of the study in order to ensure good sample quality 
for all following projects including this one [75].    
 
3.4.2. Isolation of CBMCs 
 
Within 24h after blood withdrawal in the delivery room, CBMC isolation was performed 
by a group member of the AG Schaub. 
For CBMC isolation the blood was diluted 2:1 with PBS and cells were isolated via Ficoll 
(GE Healthcare, Piscataway, USA) density centrifugation. Ficoll separates cells along 
their density gradient and thereby allows separation of mononuclear cells from 
erythrocytes. 
After centrifugation (30min, 20°C, 1400rpm, without brake), the mononuclear cell layer 
was harvested from the tube, diluted up to a volume of 10 ml with the culture medium 
RPMI (Gibco, Carlsbad, USA), centrifuged for 10 min, 2400 rpm and the supernatant 
was discarded. Cell number was determined by counting in the Neubauer counting 
chamber under the microscope.  
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After a second centrifugation step, the precipitate containing the cells was diluted in 
RPMI containing 10% human serum to a cell concentration of 5x106 cells/ ml for cell 
culture. 
 
3.4.3. Cell culture and stimulation 
 
The isolated CBMCs were stimulated with different substances triggering an immune 
response. Two of those stimuli and the control condition without any stimulation were 
analyzed in this project.  
One stimulus is Phytohaemagglutinin (PHA) with a concentration of 5µg/ml that acts as  
an unspecific activator of T cells. The other is Lipid A (LpA), the lipid component of 
Lipopolysaccharides which is an endotoxin from gram-negative bacteria, with a 
concentration of 0.1µg/ml that is known to trigger TH1 response. 
After stimulation with either 3µl PHA or LPA, the cells, among with unstimulated cells 
(Media), were incubated for 72h at 37°C temperature and a CO2 concentration of 5%. 
Subsequently, the cells were manually picked and supernatant was removed and kept at -
20°C for cytokine measurements. The resulting cells were then resuspended in PBS, the 
supernatant was spun down and discarded and the cells were infused with 1ml TRIzol 
(Invitrogen, Karlsruhe, Germany) leading to the lysis of cell membrane which is 
necessary for RNA extraction and stabilization. The samples were then stored at -80°C. 
 
3.5. Determination of gene expression  
3.5.1. RNA extraction  
 
For RNA extraction, thawed cell pellets were resuspended in 0.2 ml chloroform. After 10 
minutes incubation the mix was centrifuged for 15min at 4°C and 1200rpm. 0.5 ml 100% 
isopropanol and 1µl glycogen were added after removal of the aqueous phase. Then, the 
mix was centrifuged again, the supernatant was removed and 75 percent ethanol was 
added followed by one more centrifugation. Afterwards, the RNA precipitate was dried 
on a heating block at 42°C for 10-30 min. The resulting samples were resuspended in 
RNAse-free water, incubated at 55-60°C and then either stored at -80°C or directly used 
for further analysis. 
Sample processing down to RNA extraction took place prior to the start of this project. 
 
3.5.2. Synthesis of cDNA 
 
cDNA was synthesized following the Qiagen-Kit (QuantiTect) instructions which 
includes the elimination of possible genomic DNA (gDNA) contamination by adding a 
gDNA wipeout buffer. 
After determining the RNA concentration by photometric measurements with nanodrop 
(Peqlab by VWR, Erlangen), 1μg RNA was used for processing cDNA. 
The RNA was treated with 2 µl wipeout buffer, filled to 14 µl with RNA-free water and 
heated for 2 minutes at 42°C in the RNA-Cycler. 
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Reverse-transcriptase mix (1 µl reverse transcriptase, 4 µl QRT buffer and 1 µl primer 
mix) was added and then incubated in the cycler for 15 minutes at 42°C. 
To inactivate the reverse transcriptase, the sample was heated to 95°C for 3 minutes. The 
resulting cDNA was consequently solved in 20 μl, which lead to a final cDNA 
concentration of 50ng/μl, as 1 µl RNA was used for transcription.   
The cDNA was stored at -20°C and then used for quantitative real-time PCR. 
 
3.5.3. Primer design 
 
Primers are small nucleotide sequences that are specifically designed to bind to a certain 
gene segment. They mark the start point for the polymerase that then amplifies the gene 
sequence. Primers for the genes of interest were designed with the help of “Vector NTI” 
program (Invitrogen, Karlsruhe) and ordered from Invitrogen. 
Primer design was based upon DNA sequences provided by the genome database 
“Ensemble”, a joint project between the European Bioinformatics Institute (EBI), the 
European Molecular Biology Laboratory (EMBL) and the Wellcome Trust Sanger 
Institute (WTSI). Sequences were looked up in the “Ensemble” database and then fed 
into the “Vector NTI” program. 
In order to find a matching primer pair, which consists of a forward and a reverse primer, 
the following rules were obeyed:  
 
• Primer length should be between 18 and 27 base pairs  
• At 3´end there should be at least one guanine or cytosine 
• Melting temperature of the primer should be between 54°C and 65°C with a 
temperature difference no bigger than 0.5°C between forward and reverse primer 
• Primers have to be located behind the ATG sequence of the gene as the processed 
RNA starts at this point 
• Energy to build dimers or hair pins should be lower than ±2 kcal/mol in order to 
assure good annealing efficiency  
• Percentage of guanine and cytosine should be between 40-60% with no more than 
10% difference between forward and reverse primer 
• If possible, forward and reverse primer should be located on different exons with 
as large introns as possible in between to avoid amplification of gDNA residues 
• The resulting PCR product should be around 200 base pairs long 
Delivered primers were diluted with DEPC-water into a 1mM stock. Afterwards, a 1 μM 
dilution was made via an intermediate step of a 0.1 mM dilution. This 1 μM dilution 
contained both forward and reverse primers, was stored at +4°C and used for qRT PCR. 
The diluted primers were then tested for quality. In a first step, using a test sample, the 
general primer properties were tested with the focus on amplification and the 
corresponding melting curves. 
Primers holding up to those criteria were then tested for specificity. Therefore, they were 
tested with both gDNA and RNA and were analyzed for unwanted amplifications. 
Primers for genes with only one exon sometimes bound to gDNA. By means of the 
melting curve analysis we were never the less able to differentiate between cDNA 
22 
 
amplification and unwanted gDNA amplification. Additionally, as we added the gDNA 
wipeout buffer during RNA isolation, contamination with gDNA was highly unlikely in 
the used samples. 
 
3.5.4. Principle of PCR 
 
The polymerase chain reaction (PCR) is a technology used to specifically amplify DNA. 
Even smallest amounts of DNA (down to a single copy) are sufficient. PCR mimics the 
natural process of DNA amplification taking place e.g. in human cells. 
In a first step, the DNA double helix is decomposed by heat denaturation at 96°C, yielding 
two single-stranded DNA molecules. This step is called initialization. In addition to the 
decomposition of DNA, the high temperature activates the involved polymerase. 
Starting with the second cycle, the following steps are repeated in each PCR cycle: 
1. Denaturation:  
In the beginning, the newly formed DNA is decomposed into single strands by 
heating it up to 95°C. 
2. Annealing:  
At 62.5°C, primers anneal to the 5‘-3‘– end of the gene section to be amplified. 
This step takes about 30 seconds. Choosing the right temperature is crucial as an 
incorrect temperature my lead to non-specific amplifications. The listed 
temperatures refer to the specific conditions in this project. 
3. Elongation:  
The thermostable Taq Polymerase elongates the annealed primers at 72°C. The 
desoxynucleotide triphosphates are part of the added Mastermix. Elongation 
continues until either the Taq polymerase reaches the end of the strand or the 
process is interrupted by a new cycle of heating. 
Theoretically, amplification is an exponential process as can be seen in the following 
equation: 
 
Nn = N0 x 2n 
 
Equation 1: exponential increase of cDNA with 
Nn = amount of cDNA after n cycles 
N0 = amount of cDNA in the beginning (prior to first amplification) 
n = amount of cycles  
 
 
For this to be true, efficiency of Taq polymerase would have to be 100% leading to a 
reduplication of cDNA in each cycle. As this doesn’t apply in reality, every analysis of 
PCR data should contain a correction for efficiency. Therfore quantiatative real-time PRC 
was used in this project. 
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3.5.5. Quantitative real-time PCR 
 
In contrast to conventional PCR, quantitative real-time PCR (qRT PCR) can not only 
amplify DNA sections but also provides information about the original amount of cDNA 
in the sample. As cDNA that resulted from the mRNA of the cord blood cells was used 
in this project, this method allows investigation of the gene expression on RNA level in 
the unstimulated and stimulated CBMCs. 
Quantitative analysis in qRT PCR is mediated through a fluorescence marker that binds 
to the amplified gene segment. In this project the fluorescent dye SYBR-Green (Biorad, 
Hercules, USA) was used which intercalates into double-stranded DNA and then 
transmits a fluorescence signal. 
Reaching a certain amount of DNA product, the fluorescence signal exceeds the so-called 
threshold. The earlier this happens the higher the initial RNA concentration in the sample 
has been.  
SYBR-Green is a highly sensitive measuring system but it does not only intercalate into 
DNA but also with primer dimers and byproducts of PCR. To certify specificity, analysis 
of the melting curves is indispensable.    
 
3.5.6. Pipetting scheme  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Mincle 
M 
TLR7 
M 
TLR5 
M 
Dectin1 
M 
Dectin2 
M 
RIG-I 
M 
MDA-
5 
M 
NLRP3 
M 
Casp1 
M 
LMP2 
M 
LMP7 
M 
IL-
1R1 
M 
B Mincle 
M 
TLR7 
M 
TLR5 
M 
Dectin1 
M 
Dectin2 
 M 
RIG-I 
M 
MDA-
5 
M 
NLRP3 
M 
Casp1 
M 
LMP2 
M 
LMP7 
M 
IL-
1R1 
M 
C Mincle 
PHA 
TLR7 
PHA 
TLR5 
PHA 
Dectin1 
PHA 
Dectin2 
 PHA 
RIG-I 
PHA 
MDA-
5 
PHA 
NLRP3 
PHA 
Casp1 
PHA 
LMP2 
PHA 
LMP7 
PHA 
IL-
1R1 
PHA 
D Mincle 
PHA 
TLR7 
PHA 
TLR5 
PHA 
Dectin1 
PHA 
Dectin2 
 PHA 
RIG-I 
PHA 
MDA-
5 
PHA 
NLRP3 
PHA 
Casp1 
PHA 
LMP2 
PHA 
LMP7 
PHA 
IL-
1R1 
PHA 
E Mincle 
LpA 
TLR7 
LpA 
TLR5 
LpA 
Dectin1 
LpA 
Dectin2 
LpA 
RIG-I 
LpA 
MDA-
5 
LpA 
NLRP3 
LpA 
Casp1 
LpA 
LMP2 
LpA 
LMP7 
LpA 
IL-
1R1 
LpA 
F Mincle 
LpA 
TLR7 
LpA 
TLR5 
LpA 
Dectin1 
LpA 
Dectin2 
 LpA 
RIG-I 
LpA 
MDA-
5 
LpA 
NLRP3 
LpA 
Casp1 
LpA 
LMP2 
LpA 
LMP7 
LpA 
IL-
1R1 
LpA 
G 18S 
M 
18S 
PHA 
18S 
LpA 
B2mic 
M 
B2mic 
LpA 
Mincle 
NTC 
TLR7 
 
NTC 
TLR5 
NTC 
Dectin1 
NTC 
Dectin2 
 NTC 
RIG-I 
NTC 
MDA-
5 
NTC 
H 18S 
M 
18S 
PHA 
18S 
LpA 
B2mic 
PHA 
 NLRP3 
NTC 
Casp1 
NTC 
LMP2 
NTC 
LMP7 
NTC 
IL-1R1 
NTC 
18S 
NTC 
B2mic 
NTC 
Figure 8: pipetting scheme                     
Lines A to F represent the different stimuli (PHA, LpA) along with the unstimulated cells (M) in duplicates and column 
1-12 represent the different primers. Wells G 1-5 and H 1-4 contain the housekeeping genes and G and H 6-12 the non-
template controls (NTCs). Into every well, 5μl SSo advanced SYBR green Supermix were pipetted, followed by 1.8μl 
cDNA mix for the stimuli and 1.8μl RNAse-free water for the NTCs. Then, 3.2μl primers were added into every well 
leading to a total volume of 10μl/well. 
Pipetting was performed quickly and on ice according to the pipetting scheme in Figure 
8.  
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In addition to the selected genes for this project, 18S and β2mic, so-called housekeeping 
genes, were applied and used as reference genes. Housekeeping genes are genes that are 
constitutively expressed in a cell reflecting the base-line cell activity.  
After pipetting, the qRT PCR plates were covered with a transparent film and centrifuged 
at 2500 rpm for 15 seconds to eliminate possible air bubbles. Immediately after 
centrifugation, the plates were put into the iCycler (Biorad) and qRT PCR was performed. 
 
3.5.7. iCyler protocol  
 
Cycle 1: (1x)  95,0°C  2 minutes  
(=initialization)  
cycle 2: (40x)  
step 1: 
  
step 2+3:   
 
95,0°C  
 
62,5°C  
 
 
20 seconds 
(=denaturation)  
30 seconds 
(=annealing+  
   elongation)  
Cycle 3: (1x)  72,0°C  2 minutes  
(=Elongation)  
Cycle 4: (1x)  95,0°C  30 seconds  
Cycle 5: (1x)  55,0°C  30 seconds  
Cycle 6: (80x)  55,0°C  10 seconds  
 Cycle7: (1x) 20,0 °C HOLD 
Table 7: iCycler protocol 
 
3.5.8. Gel electrophoresis  
 
Gel electrophoresis is the separation of molecules and their fragments by using their 
different moving properties through an electric field. Positively charged molecules move 
towards the cathode whereas negatively charged move towards the anode. The smaller 
the molecule the faster and further it moves through the gel leading to a separation based 
on the different molecule sizes. 
This process is modulated by the concentration of the gel. A higher concentration of 
agarose results in a more close-mesh gel and a more precise separation of smaller 
fragments (down to 50 base pairs). Nucleic acids are negatively charged because of their 
sugar-phosphate back bone and therefore move towards the anode.  
Gel electrophoresis was used in this project to separate and assess the amplification 
products of qRT PCR.  
In order to make the 3 percent agarose gel, 6g agarose together with 200ml of 0.5-fold 
buffer (900 ml aqua bidest+100 ml 5-fold TBE) were dissolved in a heat-resistant bulb 
and then heated until the solution was clear. After a short cooling time, 70 μl ethidium 
bromide were added. Ethidium bromide intercalates into DNA making nucleic acids 
visible under UV light.  Afterwards, the gel was poured into a chamber, combs were stuck 
into it and then the gel cooled down for 30 minutes (see Figure 9). By pulling the combs 
out of the cold gel, they formed small pockets.                        
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4 μl loading dye were added to both PCR products and NTCs. Loading dye contains a 
very high percentage of glycerin and thereby weighs down the samples keeping them 
inside the pockets. PCR products, the NTCs and the so-called ladder, a reference standard 
containing DNA fragments of known length that provides a scale to estimate the size of 
the PCR products, were pipetted into the gel pockets.  
Gel electrophoresis was performed by applying electrical current at 120 V voltage and 
400mA amperage for 40 min.  
The gel was analyzed under UV light and a picture of every gel was taken. 
 
 
Figure 9: poured gel with inserted combs, photo provided by E. Klucker 
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3.5.9. Quality control  
 
3.5.9.1. Primer selection 
In order to assure PCR with ΔCT values of high quality, primers were chosen based upon 
their melting curve and their specificity for cDNA.  
 
Figure 10: work flow for primer selection 
 
3.5.9.2. Melting curve analysis 
The melting curve generated by the iCycler (see 3.5.10) was checked for unwanted or 
unspecific amplification of e.g. primer dimers or cDNA contamination. An ideal melting 
curve features a narrow and high peak and is as similar as possible between both 
duplicates. 
In contrast, primer dimers have a flat and wide melting curve which makes it possible to 
differentiate between non-specific amplifications and the wanted gene amplification (see 
Figure 11). 
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ΔCT values featuring an unspecific melting curve or with a difference greater than 1 PCR 
cycle between the duplicates were repeated and, if they still couldn’t hold up to quality 
criteria, were excluded. 
 
3.5.9.3. Quality control by gel electrophoresis 
Additionally, the PCR quality was checked for unspecific amplification by performed gel 
electrophoresis. The gel was searched for double bands indicating said unspecific 
amplification and was checked for aberrant bands by comparison of the expected size of 
PCR bands (around 200 bp) with the added ladder.   
 
Figure 12: gel with bands labeling including genes of interest, stimuli and NTCs and ladder. 
If the gel electrophoresis showed any unwanted amplification, the PCR was repeated. 
  
Figure 11:  a) example of melting curve from a  
wanted gene amplification with a narrow, high peak  
b) example of melting curve from an unwanted  
amplification with a flat, wide peak 
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3.5.10.Data analysis 
 
 
Figure 13: cDNA amplification in iCycler program. Abscissa shows the number of PCR cycles and ordinate the 
intensity of fluorescence signal. The green line represents the threshold. The interception with the threshold is called 
CT value and is used for analysis. Red line shows rise of the fluorescence signal. In this project, duplicates were 
produced. 
The axis of abscissae shows the number of PCR cycles and the axis of ordinate the 
intensity of the fluorescence signal. 
Green fluorescent signal treshold is marked by the green line (ordinate intercept 100) 
and is determined by the iCycler program. It can also be chosen manually and should be 
located at the beginning of the exponential phase of the curve progression. 
After a certain amount of amplifications, the fluorescence signal rises above the threshold 
and starts growing exponentially. This value is called CT value (threshold cycle) and is 
used for analysis. A high gene expression results in a low CT value caused by the fact that 
a high concentration of cDNA leads to an early increase of the fluorescence signal. 
Curve progression ends in the plateau phase were optimal conditions for PCR do no 
longer apply and amplification ends. As mentioned earlier, for quality control of PCR a 
melting curve analysis should be performed. 
The iCycler generates the melting curve by continuously measuring with rising 
temperature from 55°C up to 95°C in 0.5°C steps. Every PCR product has its specific 
denaturation temperature leading to a measurable decrease in the fluorescence signal. As 
mentioned, the ideal melting curve features a narrow and high peak and is as similar as 
possible between both duplicates.  
 
3.5.11.Statistical analysis 
 
Statistical analysis was performed using Excel program and SPSS Statistics program  
Version 23 and R program (R Core Team (2016). R: A language and environment for sta
tistical computing. R Foundation for Statistical Computing, Vienna, Austria,  
https://www.R-project.org/). 
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First of all, the quality proofed CT values were entered into Excel. In this step values of 
poor quality were excluded from analysis. 
Some genes were not detectable due to technical limitation. The CT value of those genes 
was defined as 40 which corresponds to the number of the last performed PCR cycle in 
the protocol. 
In a second step, to include the different base-line gene expression of every sample into 
calculation, difference between expression of the particular gene and the housekeeping 
gene 18S was calculated resulting in so-called ΔCT values. 
ΔCT= CT value genex – CT value 18S 
The expression of 18S was, as expected, higher than the expression of the genes of interest 
leading to positive ΔCT values. 
To define how the different stimuli affect the gene expression, difference between ΔCT 
values of the stimulated samples and the ΔCT of the unstimulated samples (media) was 
calculated. The resulting ΔΔCT value can either be positive as a correlate of upregulation 
or negative as a correlate of downregulation. 
ΔΔCT= ΔCT value genex media - ΔCT value genex stimulated   
One parametric model contributing to the characteristics of censoring problem within the 
gene expression data is the so-called tobit method. 
Applied to the gene expression data, only values between 1 and 40 (meaning between the 
first and the last cycle of qRT PCR) are detectable due to technical limitation. If the gene 
amplification is beyond this value, the expression of the gene is too low to be determined. 
 
In an equation: 
y=   
 
 
To calculate the mean value of y (not y*), the tobit model is applied. Furthermore, this 
model allows including additional co-variables, in this case the different phenotypes. 
Therefore, a comparison between the different phenotypes can be performed as well as 
an adjustment for possible confounders.  
To analyze whether the stimulation conditions had an effect on the gene expression, 
Wilcoxon sign ranked test was performed. 
To test for difference of the gene expression between the different wheeze phenotypes, 
Mann-Whitney-U test was performed. 
Statistical significance was defined as a p-value < 0.05.  
For genes that showed significant differential expression between the phenotypes, the 
effect of confounding study characteristics was assessed in a stratified analysis.  
  
y*      y <40 
40      y ≥ 40 
Equation 2: censoring mechanism 
 y= theoretical gene expression; y*= measured gene expression 
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4. RESULTS 
 
4.1. Phenotype definition 
 
Phenotypes were defined on the basis of questionnaires completed by the parents at both 
age 3 years and age 6 years of the children (see page 106). 
Table 8 exemplifies how the different phenotypes were defined. Shortly, healthy controls 
were defined by no symptoms at any age. Multitrigger wheeze was defined by wheezing 
caused by multiple triggers (e.g. effort, cold, house dust, animal contact, pollen, others). 
Additionally, some children featured a positive allergy test and suffered from 
rhinoconjunctivitis. Children presenting with wheeze associated to viral infection, were 
divided into two groups: early viral wheeze and persistent or late onset viral wheeze. 
Patients presenting with viral wheeze only within the first 3 years of life were defined as 
early viral wheeze. Persistent or late onset viral wheeze was defined by symptoms at age 
6 years during an acute infection in combination with age 3 years symptoms. Consistency 
of information was checked using all 3 questionnaires (birth, age 3 years and age 6 years). 
 
Table 8: phenotype characteristics based upon the 6-year questionnaire 
Phenotype Question 1: 
‘Has your child 
ever had 
wheezing?’ 
Question 2 
‘Has your child 
wheezed in the 
past 3 years?’ 
Additional questions 
Healthy 
control 
no no ‘Has your child been prescribed 
medication for wheezing or shortness of 
breath in the last 3 years?’(Question 10) : 
no 
 
‘Has your child been diagnosed with 
obstructive or spastic bronchitis or 
asthmatic bronchitis?’ (Question 34): no 
Multitrigger 
wheeze 
yes yes ‘What triggers the wheezing?’(Question 
6): at least two different triggers 
 
‘How often does your child wheeze when 
they are not having an acute 
infection?’(Question 7): at least once a 
month 
Early viral 
wheeze 
yes no ‘Is your child completely symptom-free 
between the wheezing 
episodes?’(Question 8): yes 
 
‘How often does your child wheeze when 
they’re not having an acute infection?’ 
(Question 7): never 
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Persistent or 
late onset 
viral wheeze 
yes yes ‘Is your child completely symptom-free 
between the wheezing 
episodes?’(Question 8): yes 
 
‘How often does your child wheeze when 
they’re not having an acute infection?’ 
(Question 7): never 
 
In a second step, the defined phenotypes persistent or late onset viral wheeze and 
multitrigger wheeze were characterized more closely by considering the temporal aspect. 
This means, the questionnaires were analyzed independently from each other. If the 
criteria for multitrigger wheeze applied at both ages, the multitrigger wheeze was defined 
as persistent. If the child either showed no symptoms or presented as a viral wheezer at 
age 3 but developed multitrigger-like symptoms at age 6, multitrigger wheeze was 
defined as late onset. In this step, the group of persistent and late onset viral wheeze was 
divided into either persistent viral wheeze or late onset viral wheeze by including the age 
3 years questionnaire. 
Figure 14 summarizes the phenotype characteristics. 
 
 
 
Figure 14: phenotype characteristics  
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4.2. Study characteristics 
Table 9 summarizes the study characteristics of the PAULINA/PAULCHEN sub cohort 
(n=76 children) that was analyzed in this project. The selection was based upon a case-
control design based on future phenotype definition (matching range 1:1 to 1:2). 
Statistical significance of differences between the phenotypes was analyzed using 
Kruskal-Wallis test for the continuous variables (birth weight, maternal age and maternal 
education) and Wilcoxon signed-rang for the categorical variables. The tests were 
performed by group comparison of all groups. The only statistically significant 
differences were obtained for maternal asthma when comparing healthy controls with 
children with viral wheeze and for maternal education when comparing children with 
multitrigger wheeze with children with early viral wheeze.  
Table 9: Study characteristics for the samples analyzed in this project (n total=76).  
 a= Kruskal-Wallis test 
 b= Wilcoxon signed-rang test 
  
 Healthy controls 
(HC) 
(n=26) 
Multitrigger 
wheeze (MT) 
(n=14) 
Early viral 
wheeze (EVW) 
(n=18) 
Viral wheeze 
(VW) 
(n=18) 
p-
value 
 
Male sex 10 (38.5%) 8 (57.1%) 12 (66.7%) 12 (66.7%) n.s.b  
Birth weight in grams 
3510.0 
(3146.25;3748.75) 
3737.5 
(3590.0;3965.0) 
3660.0 
(3342.5;3837.5) 
3570.0 
(3402.5;3797.5) 
n.s.a 
Maternal age at birth 
in years 
33.5 
(30.75;36.25) 
32.5 
(28.5;34.75) 
35 
(32.5;36.0) 
32.0 
(31.0;34.0) 
n.s.a 
Maternal asthma 0 (0%) 2 (14.3%) 3 (16.7%) 4 (22.2%) 
HC vs 
VW  
0.02b 
Maternal atopy 7 (26.9%) 8 (57.1%) 7 (38.9%) 10 (55.6%) n.s.b 
Maternal 
smoking 
during 
pregnancy 
1 (3.8%) 0 (0%) 1 (5.6%) 1 (5.6%) n.s.b 
stopped in 
pregnancy 
3 (11.5%) 1 (7.1%) 0 (0%) 3 (16.7%) n.s.b 
stopped 
before 
pregnancy 
0 (0%) 1 (7.1%) 0 (0%) 0 (0%) n.s.b 
never 
smoked  
22 (84.6%) 12 (85.7%) 17 (94.4%) 14 (77.8%) n.s.b 
Maternal education 
(school years) 
16.0 
(10.0;16.0) 
13.0 
(10.0;16.0) 
16.0 
(16.0;16.0) 
16.0 
(13.0;16.0) 
MT vs. 
EVW 
0.01a 
Paternal atopy 10 (30.8%) 8 (57.1%) 9 (50.0%) 6 (33.3%) n.s.b 
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4.2.1. Stratification for maternal asthma and maternal school years  
In a second step, association of gene expression and both maternal asthma and maternal 
school education were tested in order to identify potential confounding.  
There was no significant association between gene expression and maternal asthma 
detectable.  
For maternal school education three single associations were significant (p-value <0.05): 
LMP2, LMP7 and NLRP3 (all after PHA stimulation). Children of mothers with more 
school years showed a slightly lower gene expression. Therefore, these genes were 
analyzed stratified for maternal school years.  
For this analysis, the different wheeze phenotypes were divided in subgroups according 
to maternal school years leading to children with either 9, 10, 13 or 16 years of maternal 
education. In a second step, group comparisons of significant findings were recalculated 
within the stratified subgroups.  
Overall, the found upregulation of gene expression in children with multitrigger wheeze 
remained unchanged. Due to the smaller sample size in the subgroups, said upregulation 
was not as significant as in the unstratified analysis.  
For the four-group phenotype analysis, there was a tendency towards a lower gene 
expression of LMP2 and LMP7 in children with multitrigger wheeze and 16 years of 
maternal education compared with children with less maternal education years. However, 
this was not statistically significant.  
In the more detailed phenotype analysis, there was a tendency towards lower gene 
expression of NLRP3 in children with late onset multitrigger wheeze and 16 years of 
maternal education.  However, these findings were not statistically significant. 
The affected findings and associated results after stratifying for maternal school years are 
listed in the attachments (see page 120).  
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4.3. Gene expression 
In the following, the y-axis is scaled reversely. Therefore, values higher up the y-axis 
represent a lower ΔCT value meaning a higher gene expression.  
4.3.1. Technical exclusion 
Based on previous publications, we have shown that a group size of 14-16 children is 
sufficient for significant results [3, 74]. In a nested case-control study design, a 1:1 to 1:2 
matching was planned. Thus, of the total amount of n=200 children in the PAULINA 
cohort, n= 69 children were analyzed in this project. Additionally, n=7 children from the 
PAULCHEN multitrigger sub group were analyzed in order to reach an adequate sample 
size. 
One limiting factor for sample selection was the amount of cDNA available resulting in 
some samples with cDNA lacking for one or more stimuli. 
Furthermore, some ΔCT values had to be excluded from analysis as they couldn’t hold up 
to strict quality criteria. Table 10 shows the number and percentage of excluded samples 
for each gene. 
 
Table 10: number and percentage of excluded sample per gene and stimulus 
Gene Media (%) PHA(%) LpA(%) 
TLR5 1(1.3%) 6 (7.9%) 6 (7.9%) 
TLR7 1(1.3%) 2 (2.6%) 6 (7.9%) 
RIG-I (DDX58) 0 (0%) 2 (2.6%) 5 (6.6%) 
IFIH1 (MDA-5) 1(1.3%) 1 (1.3%) 4 (5.3%) 
Mincle 2 (2.6%) 4 (5.3%) 4 (5.3%) 
Dectin1 2 (2.6%) 2 (2.6%) 4 (5.3%) 
Dectin2 5 (6.6%) 5 (6.6%) 6 (7.9%) 
LMP2 0 (0%) 1 (1.3%) 4 (5.3%) 
LMP7 0 (0%) 3 (3.9%) 7 (9.2%) 
NLRP3 0 (0%) 3 (3.9%) 4 (5.3%) 
Casp1 1(1.3%) 1 (1.3%) 4 (5.3%) 
IL-1R1 1(1.3%) 1 (1.3%) 5 (6.6%) 
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4.3.2. Detection levels of gene expression 
Due to technical limitations, some genes were not detectable. Therefore, these genes were 
set at a ΔCT value of 40 which corresponds to the last performed PCR cycle (see 3.5.11).  
Table 11 shows the percentage of uncensored data for every gene within those that were 
included for analysis. Only Dectin2 featured less than 80% uncensored data.  
 
Table 11: percentage of uncensored samples for each gene and stimulus within included data 
Gene Media % PHA % LpA(%) 
TLR5 88.0 80.0 91.4 
TLR7 81.2 85.1 92.9 
RIG-I (DDX58) 88.2 93.2 98.6 
IFIH1 (MDA-5) 86.7 88.0 95.8 
Mincle 89.2 93.1 98.6 
Dectin1 94.6 91.9 98.6 
Dectin2 43.7 63.4 87.1 
LMP2 96.1 100.0 100.0 
LMP7 88.1 95.9 98.6 
NLRP3 90.8 87.7 96.6 
Casp1 90.7 93.3 98.6 
IL-1R1 82.7 88.0 94.4 
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4.3.3. Gene- gene correlations  
The calculation of gene-gene correlations was performed using pair-wise-complete 
spearman correlations and showed a positive correlation with an average correlation 
coefficient around 0.6.  
Figure 15: gene-gene correlations  
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4.3.4. Increased gene expression after CBMC stimulation 
The following results show the differences between the stimulation conditions (media 
meaning unstimulated, PHA and LpA) for the expression of each gene independent of the 
different phenotype classification.  
Wilcoxon signed rank test was calculated based on the null hypothesis that the distribution 
of x-y (LpA – M; PHA-M) is symmetric around 0. 
Boxplots show first and third quartiles (box) and median (line). Whiskers are extended to 
the most extreme data point that is no more than 1.5 x IQR (inter quartile range) from the 
edge of the box. Data beyond the end of the whiskers are plotted as points (<1.5 IQR) or 
stars (< 3 IQR). 
 
4.3.4.1. TLR5 
Table 12: median and 95% CI for ΔCT values of 
TLR5. 
 
 
 
For TLR5, stimulation with LpA resulted in significantly upregulated gene expression (vs 
unstimulated and PHA-stimulated cells). 
TLR5 n median 95% CI  
media 75 17.61 16.55;18.00 
PHA 70 17.34 17.01;18.25 
LpA 70 15.67 15.49;16.79 
TLR5 p-value  
m vs PHA 0.95 
m vs LPA < 0.001 
LpA vs PHA < 0.001 
Figure 16:  ΔCT of TLR5 in the different stimulation  
conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
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4.3.4.2. TLR7 
 
Table 13: median and 95% CI for ΔCT values  of 
TLR7. 
 
 Both LpA and PHA stimulation conditions resulted in significant upregulation of TLR7 
gene expression. 
 
4.3.4.3. RIG-I (DDX58) 
 Table 14: median and 95% CI for ΔCT values of 
RIG-I 
 
 
 
 
For RIG-I, both stimulation conditions led to a significant upregulation of gene 
expression, with LpA stimulation resulting in a significantly higher gene expression than 
PHA. 
  
TLR7 n median 95% CI 
media 75 17.56 16.82;18.49 
PHA 74 15.77 15.66;16.97 
LpA 70 16.29 15.78;17.02 
RIG-I n median 95% CI 
media 76 15.15 14.70;15.83 
PHA 74 12.97 12.86;14.03 
LpA 71 12.61 12.33;13.13 
RIG-I p-value  
m vs PHA < 0.001 
m vs LPA < 0.001 
LpA vs PHA 0.009 
Figure 17: ΔCT of TLR7 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
Figure 18: ΔCT of RIG-I in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
TLR7 p-value  
m vs PHA 0.001 
m vs LPA < 0.001 
LpA vs PHA 0.34 
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4.3.4.4.  MDA-5 (IFIH1)  
  
Table 15: median and 95% CI for ΔCT values of 
MDA-5 
 
 
For MDA-5, the stimulation with both PHA and LPA resulted in significant upregulation 
of the gene expression. 
 
4.3.4.5. Mincle (CLEC4E) 
 Table 16: median and 95% CI for ΔCT values of 
Mincle. 
 
 
 
 
For Mincle, both stimulation conditions resulted in an upregulation of the gene expression 
with LpA showing the strongest effect. 
  
MDA-5 n median 95% CI 
media 75 14.20 13.57;15.08 
PHA 75 12.30 12.33;14.04 
LpA 72 11.75 11.81;13.21 
Mincle n median 95% CI 
media 74 13.32 12.63;14.04 
PHA 72 12.14 11.53;13.07 
LpA 72 9.52 9.15;10.43 
Mincle p-value  
m vs PHA 0.038 
m vs LPA < 0.001 
LpA vs PHA < 0.001 
Figure 20: ΔCT of Mincle in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
 
Figure 19: ΔCT of MDA-5 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
MDA-5 p-value  
m vs PHA 0.024 
m vs LPA < 0.001 
LpA vs PHA 0.11 
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4.3.4.6. Dectin1 (CLEC7A) 
Table 17: median and 95% CI for ΔCT values of 
Dectin1. 
 
 
 
 
 
For Dectin1, the stimulation with PHA led to a significant downregulation of the gene 
expression compared with both unstimulated cells and LpA stimulation. 
 
4.3.4.7.  Dectin2 (CLEC6A) 
       Table 18: median and 95% CI for ΔCT values of 
Dectin2. 
 
 
 
 
For Dectin2, both stimulation conditions affected the gene expression, with LpA 
stimulation resulting in a significantly higher gene expression than PHA. These findings 
must be seen in context with the high non-detection rate meaning a limited informative 
value. 
 
Dectin1 n median 95% CI 
media 74 11.58 11.33;12.37 
PHA 74 13.03 12.97;14.22 
LpA 72 11.82 11.68;12.73 
Dectin1 p-value  
m vs PHA < 0.001 
m vs LPA 0.24 
LpA vs PHA < 0.001 
Dectin2 n median 95% CI 
media 71 20.73 19.99;21.42 
PHA 71 18.49 18.36;19.93 
LpA 70 16.29 16.15;17.45 
Dectin2 p-value  
m vs PHA 0.007 
m vs LPA < 0.001 
LpA vs PHA < 0.001 
Figure 21: ΔCT of Dectin1 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
Figure 22: ΔCT of Dectin2 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
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4.3.4.8. LMP2 
Table 19: median and 95% CI for ΔCT values of 
LMP2. 
 
 
 
For LMP2, both stimulation conditions resulted in a significant upregulation of gene 
expression. 
4.3.4.9. LMP7 
Table 20: median and 95% CI for ΔCT values of 
LMP7. 
 
 
For LMP7, both stimulation conditions resulted in a significant upregulating effect on the 
gene expression. 
  
LMP2 n median 95% CI 
media 76 12.95 12.03;13.67 
PHA 75 9.38 9.44;10.49 
LpA 72 10.12 9.76;10.70 
LMP2 p-value  
m vs PHA < 0.001 
m vs LPA < 0.001 
LpA vs PHA 0.29 
LMP7 n median 95% CI 
media 76 12.11 12.26;13.78 
PHA 73 9.71 9.77;11.17 
LpA 69 10.22 10.05;11.09 
LMP7 p-value  
m vs PHA < 0.001 
m vs LPA < 0.001 
LpA vs PHA 0.17 
Figure 23: ΔCT of LMP2 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
Figure 24: ΔCT of LMP7 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
42 
 
4.3.4.10. NLRP3 
 Table 21: median and 95% CI for ΔCT values of 
NLRP3. 
 
  
  
 
For NLRP3, both stimulation conditions led to a significant downregulation of gene 
expression with PHA showing the strongest effect. 
 
4.3.4.11. Casp1 
 Table 22: median and 95% CI for ΔCT values of 
Casp1. 
 
 
 
For Casp1, the stimulation with LPA resulted in significant upregulation of the gene 
expression. 
 
 
NLRP3 n median 95% CI 
media 76 12.69 12.52;13.53 
PHA 73 15.10 15.17;16.31 
LpA 72 13.64 13.29;14.10 
Casp1 n median 95% CI 
media 75 12.42 11.76;13.17 
PHA 75 11.30 11.10;12.48 
LpA 72 10.05 9.87;11.00 
Casp1 p-value  
m vs PHA 0.16 
m vs LPA < 0.001 
LpA vs PHA < 0.001 
Figure 25: ΔCT of NLRP3 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
Figure 26: ΔCT of Casp1 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
 
NLRP3 p-value  
m vs PHA < 0.001 
m vs LPA 0.0058 
LpA vs PHA < 0.001 
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4.3.4.12. IL-1R1 
Table 23: median and 95% CI for ΔCT values of IL-
1R1. 
 
 
 
 
For IL-1R1, the stimulation with LPA resulted in significant upregulation of the gene 
expression. 
 
  
IL-1R1 n median 95% CI 
media 75 15.75 15.43;16.81 
PHA 75 15.31 15.26;16.45 
LpA 71 14.69 14.30;15.45 
IL-1R1 p-value  
m vs PHA 0.88 
m vs LPA < 0.001 
LpA vs PHA < 0.001 
Figure 27: ΔCT of IL-1R1 in the different stimulation conditions 
p-value: ≤0.05=* ≤0.01= **  ≤ 0.005=***  
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4.3.5. Differences in gene expression of the innate immune system 
among the wheeze phenotypes 
 
The following results show the difference between the gene expression of the phenotypes 
defined according to 4.1. 
The following abbreviations were used: 
HC=healthy control (n=26)      EVW= early viral wheeze (n=18) 
MT=multitrigger wheeze (n=14)    VW= viral wheeze (persistent and late onset) (n=18)
To test for difference of the gene expression between the different wheeze phenotypes, 
Mann-Whitney-U test was performed. 
Boxplots show first and third quartiles (box) and median (line). Whiskers are extended to 
the most extreme data point that is no more than 1.5 x IQR (inter quartile range) from the 
edge of the box. Data beyond the end of the whiskers are plotted as points (<1.5 IQR) or 
stars (< 3 IQR). 
4.3.5.1. TLR5 
 
 
Figure 28: Difference between the wheeze phenotypes for the gene expression of TLR5.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
 
 
For TLR5, there was a significant difference detectable following PHA stimulation (in 
green). MT wheeze showed the highest gene expression compared with HC (p-value= 
0.020), EVW (p-value=0.0028) and VW (p-value= 0.028). 
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4.3.5.2. TLR7 
 
Figure 29: Difference between the wheeze phenotypes for the gene expression of TLR7.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
Table 24: Difference between the wheeze phenotypes for the gene expression of TLR5 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
 
  
 
TLR5 n median 95% CI 
HC M 26 17.63 16.35;18.68 
 PHA 24 17.21 16.80;19.33 
LpA 26 15.77 15.06;17.23 
MT M 13 17.61 15.98;19.00 
 PHA    13 15.86 14.77;17.03 
LPA 12 15.59 14.57;18.41 
EVW M 18 17.54 15.03;19.12 
 PHA 17 18.17 17.11;19.05 
LPA 18 15.35 14.15;17.54 
VW M 18 17.40 15.45;18.53 
 PHA 16 17.83 16.45;19.37 
LPA 14 16.02 15.29;17.13 
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For TLR7, there was a significant upregulation for EVW compared to VW after LpA 
stimulation (p-value= 0.012) detectable. Furthermore, there was a trend towards higher 
gene expression in MT compared with VW following PHA-stimulation (p-value=0.092). 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5.3. RIG-I (DDX58) 
 
Figure 30: Difference between the wheeze phenotypes for the gene expression of RIG-I. 
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
TLR7 n median 95% CI 
HC M 25 17.92 16.80;20.02 
 PHA 26 15.85 15.69;18.20 
LpA 26 15.98 15.66;17.52 
MT M 14 16.41 15.25;18.66 
 PHA 14 14.96 14.16;16.29 
LPA 11 16.65 14.76;19.26 
EVW M 18 16.40 14.69;18.55 
 PHA 17 15.35 14.29;16.37 
LPA 18 14.97 13.91;17.02 
VW M 18 17.81 16.50;19.86 
 PHA 17 16.31 15.56;18.95 
LPA 15 16.75 16.12;17.45 
Table 25: Difference between the wheeze phenotypes for the gene expression of TLR7 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
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For RIG-I, there were no statistically significant differences between the phenotypes 
detectable. 
 
 
 
 
 
 
 
 
4.3.5.4. MDA-5 (IFIH1) 
 
Figure 31: Difference between the wheeze phenotypes for the gene expression of MDA-5. 
p-value :  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
For MDA-5 there was a trend for a lower gene expression in VW in media compared with 
EVW (p-value=0.066) and HC (p-value=0.052), after PHA stimulation compared with 
Table 26: Difference between the wheeze phenotypes for the gene expression of RIG-I on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
RIG-I n median 95% CI 
HC M 26 15.15 14.45;16.33 
 PHA 26 13.04 12.61;14.38 
LpA 26 12.54 11.89;13.30 
MT M 14 14.43 13.28;17.23 
 PHA 14 12.44 11.31;14.13 
LPA 11 12.63 11.33;13.80 
EVW M 18 14.71 13.57;15.97 
 PHA 18 13.33 12.03:13.93 
LPA 18 12.04 11.68;13.68 
VW M 18 15.44 14.62;16.56 
 PHA 16 13.20 12.68;16.33 
LPA 16 13.20 12.49;13.71 
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MT (p-value= 0.062) and following LpA stimulation compared with EVW (p-value= 
0.081), although not statistically significant.  
 
 
 
 
 
 
 
 
 
 
4.3.5.5. Mincle (CLEC4E) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 27: Difference between the wheeze phenotypes for the gene expression of MDA-5 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
MDA-5 n median 95% CI 
HC M 26 13.99 13.04;15.04 
 PHA 26 12.11 11.90;14.80 
LpA 26 11.64 11.25;13.72 
MT M 14 12.98 11.19;16.57 
 PHA 14 12.01 10.10;13.52 
LPA 12 12.53 10.44;15.14 
EVW M 17 13.12 12.08;15.32 
 PHA 18 12.52 10.94;13.83 
LPA 18 10.91 10.42;13.63 
VW M 18 15.50 14.18;17.20 
 PHA 17 13.49 12.47;17.33 
LPA 16 12.70 11.80;13.93 
 
Figure 32: Difference between the wheeze phenotypes for the gene expression of Mincle. 
p-value :  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
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For Mincle, there was a trend for a lower gene expression in VW after PHA stimulation 
compared with MT (p-value=0.081) and after LpA stimulation compared with EVW (p-
value= 0.055), although not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5.6. Dectin1 (CLEC7A) 
 
 
Figure 33: Difference between the wheeze phenotypes for the gene expression of Dectin1 
p-value :  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
Table 28: Difference between the wheeze phenotypes for the gene expression of Mincle on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
Mincle n mean 95% CI 
HC M 25 13.38 
11.96 
9.28 
12.59;14.16 
11.11;13.08 
8.68;11.32 
 PHA 25 
LpA 26 
MT M 14 13.01 1.61;15.44 
9.65;13.42 
8.20;11.47 
 PHA 14 11.95 
LPA 12 9.64 
EVW M 17 13.12 11.60;14.65 
10.24;13.15 
7.71;10.43 
 PHA 18 11.95 
LPA 18 8.41 
VW M 18 13.72 11.96;15.48 
11.61;16.54 
9.25;11.18 
 PHA 15 12.99 
LPA 16 10.19 
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For Dectin1, there was a significantly higher gene expression in MT following PHA 
stimulation compared with VW (p-value= 0.012) and with EVW (p-value= 0.037) and a 
trend for higher gene expression compared with HC (p-value=0.063). The gene 
expression in MT also tended to be higher in media compared with VW (p-value=0.097) 
and with HC (p-value=0.051). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 29: Difference between the wheeze phenotypes for the gene expression of Dectin1 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
Dectin1 n median 95% CI 
HC M 26 11.82 11.28;13.08 
 PHA 25 13.23 12.55;14.50 
LpA 26 11.54 11.07;13.05 
MT M 13 10.19 9.29;12.55 
 PHA 14 11.82 10.62;13.71 
LPA 12 11.52 10.46;14.24 
EVW M 17 12.12 10.67;12.78 
 PHA 18 13.83 12.56;14.89 
LPA 18 11.75 11.09;13.23 
VW M 18 11.57 11.15;13.18 
 PHA 17 14.39 13.10;16.40 
LPA 16 12.24 11.71;13.06 
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4.3.5.7. Dectin2 (CLEC6A) 
 
Figure 34: Difference between the wheeze phenotypes for the gene expression of Dectin2.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
  
For Dectin2, there were no statistically significant differences identifiable between the 
wheeze phenotypes.  
  Dectin2 n median 95% CI 
HC M 24 20.55 19.27;21.85 
 PHA 24 18.28 17.59;20.52 
LpA 25 15.71 15.15;17.84 
MT M 11 21.42 19.20;22.19 
 PHA 12 17.40 15.85;20.29 
LPA 12 16.40 15.83;19.60 
EVW M 18 21.26 18.94;22.19 
 PHA 18 18.65 17.85;21.19 
LPA 17 16.19 15.54;17.23 
VW M 18 21.40 19.37;22.70 
 PHA 17 19.38 18.06;21.21 
LPA 16 17.06 15.65;18.43 
Table 30: Difference between the wheeze phenotypes for the gene expression of Dectin2 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
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4.3.5.8. LMP2 
 
 
Figure 35: Difference between the wheeze phenotypes for the gene expression of LMP2.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
  
For LMP2, there was a trend for a higher gene expression in MT compared with HC (p-
value=0.056) after PHA stimulation, although not statistically significant. 
 
 
 
 
 
 
 
 
Table 31: Difference between the wheeze phenotypes for the gene expression of LMP2 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
 
LMP2 n median 95% CI 
HC M 26 12.98 12.08;13.90 
 PHA 26 9.76 9.36;11.24 
LpA 26 10.19 9.25;10.64 
MT M 14 12.68 10.54;15.07 
 PHA 14 8.71 8.01;10.24 
LPA 12 10.26 8.72;11.86 
EVW M 18 11.37 10.92;13.83 
 PHA 18 9.45 8.82;10.94 
LPA 18 9.67 9.13;11.73 
VW M 18 13.15 12.11;15.35 
 PHA 17 9.18 8.91;11.59 
LPA 16 10.19 9.76;11.10 
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4.3.5.9. LMP7 
 
 
Figure 36: Difference between the wheeze phenotypes for the gene expression of LMP7.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
 
For LMP7, there was a trend for a higher gene expression in MT compared with EVW 
(p-value=0.084) following PHA stimulation, although not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
Table 32: Difference between the wheeze phenotypes for the gene expression of LMP7 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
LMP7 n median 95% CI 
HC M 26 12.08 11.58;13.87 
 PHA 26 9.89 9.51;12.13 
LpA 25 10.15 9.43;11.12 
MT M 14 11.32 9.81;15.17 
 PHA 14 8.94 8.17;10.52 
LPA 11 10.63 9.19;11.42 
EVW M 18 13.04 11.81;14.84 
 PHA 17 9.95 9.39;11.76 
LPA 17 10.01 9.38;12.56 
VW M 18 12.41 11.90;15.18 
 PHA 16 9.33 8.71;12.84 
LPA 16 10.31 10.02;11.57 
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4.3.5.10. NLRP3 
 
 
 
For NLRP3 there was a significant higher gene expression in MT in both media compared 
with VW (p-value=0.028), EVW (p-value=0.024) a trend compared with HC (p-
value=0.081) and after PHA stimulation in MT compared with VW (p-value=0.005), EVW 
(p-value=0.013) and HC (p -value=0.015). 
 
 
 
 
 
 
 
 
 
Table 33: Difference between the wheeze phenotypes for the gene expression of NLRP3 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
NLRP3 n median 95% CI 
HC M 26 12.69 12.21;13.57 
 PHA 26 15.26 14.74;16.54 
LpA 26 13.28 12.78;14.38 
MT M 14 11.85 10.71;12.88 
 PHA 14 14.30 13.39;15.65 
LPA 12 13.20 12.62;14.68 
EVW M 18 12.73 12.43;14.53 
 PHA 17 15.56 14.65;16.74 
LPA 18 13.77 12.87;14.83 
VW M 18 12.84 12.28;15.18 
 PHA 16 16.07 15.34;18.67 
LPA 16 13.90 13.19;14.30 
Figure 37: Difference between the wheeze phenotypes for the gene expression of NLRP3.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
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4.3.5.11. Casp1 
 
 
Figure 38: Difference between the wheeze phenotypes for the gene expression of Casp1. 
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
For Casp1, there were no statistically significant differences identifiable between the 
wheeze phenotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
Casp1 n median 95% CI 
HC M 25 12.52 11.67;13.20 
 PHA 26 11.46 10.95;12.85 
LpA 26 9.96 9.40;11.20 
MT M 14 11.71 9.60;14.13 
 PHA 14 10.87 9.23;12.79 
LPA 12 10.28 8.98;12.80 
EVW M 18 12.07 10.56;13.87 
 PHA 18 11.48 9.82;12.37 
LPA 18 9.74 8.48;11.13 
VW M 18 12.86 11.51;14.97 
 PHA 17 11.17 10.98;15.04 
LPA 16 10.98 10.08;11.95 
 
Table 34: Difference between the wheeze phenotypes for the gene expression of Casp1 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
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4.3.5.12. IL-1R1 
 
 
Figure 39: Difference between the wheeze phenotypes for the gene expression of IL-1R1. 
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
 
For IL-1R1 there was a trend for a lower expression in VW in media compared with MT 
(p-value=0.071) and with HC (p-value=0.055). After PHA stimulation, the gene 
expression in MT was significantly higher compared with VW (p-value=0.003) and tended 
to be higher compared with EVW (p-value=0.08). Additionally, the expression was 
significantly lower in VW compared with HC (p-value=0.033). After LpA stimulation, the 
gene expression was significantly lower in VW compared with MT (p-value=0.03) and 
tended to be lower compared with EVW (p-value=0.076). 
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IL-1R1 n median 95% CI 
HC M 25 15.57 14.77;16.93 
 PHA 26 15.02 14.63;16.58 
LpA 26 14.82 13.78;16.13 
MT M 14 15.15 13.10;17.54 
 PHA 14 14.56 13.27;15.79 
LPA 11 14.06 12.45;16.30 
EVW M 18 15.51 14.40;17.48 
 PHA 18 15.80 14.67;17.00 
LPA 18 14.13 13.44;15.65 
VW M 18 16.52 15.99;18.61 
 PHA 17 16.72 15.93;18.79 
LPA 16 15.59 14.78;16.18 
Table 35: Difference between the wheeze phenotypes for the gene expression of IL-1R1 on ΔCT level within the 
different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
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4.3.6. Gene expression patterns  
Table 36 shows a general overview of gene expression patterns. Significant results are 
marked in green (p-value <0,05); trends are marked in orange (p-value < 0,1). 
Table 36: Overview of gene expression patterns 
 TLR5 
media     PHA      LpA 
TLR7 
media     PHA      LpA 
RIG-I 
media     PHA      LpA 
MDA-5 
media     PHA      LpA 
MT vs 
VW 
MT ↓ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ 
MT vs 
EVW 
MT ↓ MT ↑ MT ↓ MT ↓ MT ↑ MT ↓ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↓ 
MT vs 
HC 
MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↓ 
VW vs 
EVW 
VW ↑ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ 
VW vs 
HC 
VW↑ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↓ VW↓ VW↓ 
EVW vs 
HC 
EVW 
↑ 
EVW 
↓ 
EVW 
↑ 
EVW 
↑ 
EVW
↑ 
EVW 
↑ 
EVW 
↑ 
EVW 
↓ 
EVW 
↑ 
EVW 
↑ 
EVW 
↓ 
EWV 
↑ 
 
 Mincle 
media     PHA      LpA 
Dectin1 
media     PHA      LpA 
Dectin2 
media     PHA      LpA 
LMP2 
media     PHA      LpA 
MT vs 
VW 
MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ MT ↑ MT ↓ 
MT vs 
EVW 
MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↓ MT ↓ MT ↑ MT ↓ 
MT vs 
HC 
MT ↑ MT ↓ MT ↓ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↓ MT ↑ MT ↑ MT ↓ 
VW vs 
EVW 
VW↓ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↓ VW↑ VW↓ 
VW vs 
HC 
VW↓ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↓ VW↑ VW
↔ 
EVW vs 
HC 
EVW 
↑ 
EVW 
↓ 
EVW 
↑ 
EVW 
↓ 
EVW 
↓ 
EVW 
↓ 
EVW 
↓ 
EVW 
↓ 
EVW 
↓ 
EVW 
↑ 
EVW 
↑ 
EVW 
↑ 
 
 LMP7 
media     PHA      LpA 
NLRP3 
media     PHA      LpA 
Casp1 
media     PHA      LpA 
IL-1R1 
media     PHA      LpA 
MT vs 
VW 
MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ 
MT vs 
EVW 
MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ 
MT vs 
HC 
MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ MT ↑ MT ↑ MT ↓ MT ↑ MT ↑ MT ↑ 
VW vs 
EVW 
VW↑ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ 
VW vs 
HC 
VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ VW↓ VW↑ VW↓ VW↓ VW↓ VW↓ 
EVW vs 
HC 
EVW 
↓ 
EVW 
↓ 
EVW 
↑ 
EVW 
↓ 
EVW 
↓ 
EVW 
↓ 
EVW 
↑ 
EVW 
↓ 
EVW 
↑ 
EVW 
↑ 
EVW 
↓ 
EVW 
↑ 
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4.3.7. Differentially expressed genes of the innate immune system 
considering temporal aspects of wheezing symptoms 
 
In a second step, the phenotypes were divided into more precise groups. Here, the 
variation over time was factored into analysis. 
This resulted in the phenotypes ‘persistent multitrigger wheeze’ (multitrigger wheeze at 
both age 3 and age 6), ‘late onset multitrigger wheeze’ (viral wheeze or healthy at age 3, 
multitrigger wheeze at age 6), ‘early viral wheeze’ (viral wheeze at age 3, healthy at age 
6), ‘persistent viral wheeze’ (viral wheeze at age 3 and age 6) and ‘late onset viral wheeze’ 
(healthy at age 3, viral wheeze at age 6), see 4.1. This led to a smaller sample size within 
the subgroups (see below). 
The following abbreviations were used: 
HC=healthy control (n=26) 
PMT=persistent multitrigger wheeze (n=4) 
LOM=late onset multitrigger wheeze (n=10) 
EVW=early viral wheeze (n=18) 
PVW=persistent viral wheeze (n=11)  
LOVW=late onset viral wheeze (n=6)
Boxplots show first and third quartiles (box) and median (line). Whiskers are extended to 
the most extreme data point that is no more than 1.5 x IQR (inter quartile range) from the 
edge of the box. Data beyond the end of the whiskers are plotted as points (<1.5 IQR) or 
stars (< 3 IQR). 
 
4.3.7.1. TLR5 
 
Figure 40: Difference between the detailed wheeze phenotypes for the gene expression of TLR5.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
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In the more detailed analysis, children with PMT also showed a higher gene expression 
following PHA stimulation. PMT showed significantly higher gene expression compared 
with HC (p-value=0.029), PVW (p-value=0.036)) and EVW (p-value=0.004). LOM also 
showed a higher gene expression in PHA compared with EVW (p-value=0.034) and a trend 
to a higher gene expression compared with PVW (p-value=0.095). 
 
Table 37: Difference between the detailed wheeze phenotypes for the gene expression of TLR5 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TLR5 n median 95% CI 
HC M 26 17.63 16.35;18.68 
 PHA 24 17.21 16.80;19.33 
LpA 26 15.77 15.06;17.23 
PMT M 3 17.61 13.00;21.67 
 PHA 4 15.58 14.89;16.18 
LPA 3 15.38 11.32;18.58 
LOM M 10 17.58 15.56;19.51 
 PHA 9 16.76 14.33;17.79 
LpA 9 15.79 14.48;19.54 
EVW M 18 17.54 15.03;19.12 
 PHA 17 18.17 17.11;19.05 
LPA 18 15.35 14.15;17.54 
PVW M 11 17.99 16.85;19.53 
 PHA 10 16.87 12.87;21.36 
LpA 10 16.02 15.20;17.25 
LOVW M 6 16.39 14.23;18.44 
 PHA 5 16.87 12.87;21.36 
LPA 4 15.92 12.66;19.67 
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4.3.7.2. TLR7 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
For TLR7, the more detailed analysis also showed a higher gene expression in 
multitrigger wheezing after PHA stimulation. PMT showed significantly higher gene 
expression compared with HC (p-value= 0.035) and with PVW (p-value=0.0395). In media, 
LOM showed significantly higher gene expression than PVW (p-value=0.036). After LpA 
stimulation, EVW showed higher gene expression than both LOM (p-value=0.035) and 
PVW (p-value=0.004).  
  
Figure 41: Difference between the detailed wheeze phenotypes for the gene expression of TLR7.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
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4.3.7.3. RIG-I (DDX58)  
 
Figure 42: Difference between the detailed wheeze phenotypes for the gene expression of RIG-I  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
 
Table 38: Difference between the detailed wheeze phenotypes for the gene expression of TLR7 on ΔCT level 
within the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
 
TLR7 n median 95% CI 
HC M 25 17.92 16.80;20.02 
 PHA 26 15.85 15.69;18.19 
LpA 26 15.98 15.66;17.52 
PMT M 4 17.01 10.70;22.04 
 PHA 4 13.70 12.06;16.48 
LPA 3 14.03 6.64;22.27 
LOM M 10 16.40 15.14;19.23 
 PHA 10 15.56 14.24;16.99 
LpA 8 17.05 15.41;20.52 
EVW M 18 16.41 14.69;18.55 
 PHA 17 15.35 14.29;16.37 
LPA 18 14.97 13.91;17.02 
PVW M 11 17.82 17.22;20.45 
 PHA 11 16.31 15.14;19.86 
LpA 10 17.10 16.38;17.96 
LOVW M 6 17.70 15.37;21.69 
 PHA 5 16.69 12.90;21.33 
LPA 4 16.40 13.95;17.87 
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For RIG-I, the more detailed analysis revealed a higher gene expression in EVW 
compared with PVW (p-value= 0.055) in media. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.7.4. MDA-5 (IFIH1) 
 
 
 
 
RIG-I n median 95% CI 
HC M 26 15.15 14.45;16.33 
 PHA 26 13.04 12.61;14.38 
LpA 26 12.54 11.89;13.31 
PMT M 4 14.47 9.63;18.47 
 PHA 4 11.77 9.15;14.10 
LPA 3 10.71 5.99;15.98 
LOM M 10 14.43 13.11;18.36 
 PHA 10 12.71 11.26;15.06 
LpA 8 13.07 11.92;14.44 
EVW M 18 14.71 13.57;15.97 
 PHA 18 13.33 12.03;13.93 
LPA 18 12.04 11.68;13.68 
PVW M 11 15.57 14.95;17.18 
 PHA 11 12.47 12.09;15.89 
LpA 10 13.23 12.67;13.71 
LOVW M 6 14.93 12.08;17.01 
 PHA 4 16.99 8.18;24.41 
LPA 5 12.61 10.48;14.96 
Table 39: Difference between the detailed wheeze phenotypes for the gene expression of RIG-I on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
Figure 43: Difference between the detailed wheeze phenotypes for the gene expression of MDA-5.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
 
64 
 
For MDA-5, the more detailed analysis showed a higher gene expression for multitrigger 
wheezing following PHA stimulation. PMT showed significantly higher gene expression 
compared with HC (p-value=0.044) and PVW (p-value=0.026) and a trend to a higher gene 
expression than EVW (p-value=0.081) and LOVW (p-value=0.063). The gene expression 
in PMT was also higher than in LOM (p-value=0.054). In media, PVW showed a trend 
to the lowest gene expression compared with both HC (p-value=0.065) and EVW (p-
value=0.082). The same could be seen after LpA stimulation, for PVW had a lower gene 
expression than PMT (p-value=0.077) and EVW (p-value=0.0799). Additionally, LOVW 
showed a lower gene expression than LOM (p-value=0.075) following PHA stimulation. 
 
 
 
 
 
 
 
 
 
 
 
  
Table 40: Difference between the detailed wheeze phenotypes for the gene expression of MDA-5 on ΔCT level 
within the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
MDA-5 n median 95% CI 
HC M 26 13.99 13.04;15.04 
 PHA 26 12.11 11.90;14.80 
LpA 26 11.64 11.25;13.72 
PMT M 4 12.34 3.22;21.42 
 PHA 4 9.67 6.3;13.08 
LPA 3 9.93 2.79;16.93 
LOM M 10 12.98 11.39;17.62 
 PHA 10 12.37 10.58;14.73 
LpA 9 13.15 11.05;16.49 
EVW M 17 13.12 12.08;15.32 
 PHA 18 12.52 10.94;13.83 
LPA 18 10.91 10.42;13.63 
PVW M 11 15.08 13.84;18.23 
 PHA 11 12.46 11.18;17.17 
LpA 10 12.96 11.68;14.33 
LOVW M 6 15.12 11.78;18.15 
 PHA 5 20.56 10.76;23.81 
LPA 5 12.38 9.30;15.96 
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4.3.7.5. Mincle (CLEC4E) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Difference between the detailed wheeze phenotypes for the gene expression of Mincle. 
 p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=***  
 
For Mincle, the detailed analysis showed a lower gene expression in PVW in media 
compared with PMT (p-value= 0.056) and LOVW (p-value=0.078). This downregulation 
was significant for PVW after LpA stimulation compared with PMT (p-value =0.028) and 
with EVW (p-value=0.047). Additionally, LOM showed a trend towards a lower gene 
expression than EVW (p-value=0.068). 
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4.3.7.6. Dectin1 (CLEC7A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Difference between the detailed wheeze phenotypes for the gene expression of Dectin1.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
Table 41: Difference between the detailed wheeze phenotypes for the gene expression of Mincle on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
Mincle n median 95% CI 
HC M 25 13.38 12.59;14.17 
 PHA 25 11.69 11.11;13.08 
LpA 26 9.28 8.68;11.32 
PMT M 4 11.76 5.90;16.12 
 PHA 4 11.59 6.16;14.71 
LPA 3 8.3 1.65;13.47 
LOM M 10 13.68 10.69;16.99 
 PHA 10 12.17 9.48;14.47 
LpA 9 10.37 8.85;12.32 
EVW M 17 13.12 11.60;14.65 
 PHA 18 12.55 10.52;16.21 
LPA 18 8.41 7.71;10.43 
PVW M 11 14.31 12.65;17.46 
 PHA 10 12.15 10.17;16.65 
LpA 10 10.19 9.32;11.48 
LOVW M 6 12.13 9.01;14.42 
 PHA 4 16.87 6.13;25.87 
LPA 5 8.83 6.52;12.93 
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For Dectin1, the detailed analysis showed a higher gene expression in multitrigger 
wheezing. In media, LOM showed a trend to a higher gene expression than PVW (p-
value=0.095) and HC (p-value=0.086). After PHA stimulation, PMT showed 
significantly higher gene expression than PVW (p-value=0.043) and higher gene 
expression than EVW (p-value=0.053) and HC (p-value=0.062). LOM also showed a 
trend towards a higher gene expression than PVW (p-value= 0.098). After LpA 
stimulation, PMT showed a higher gene expression than PVW (p-value=0.078). 
 
 
 
 
 
 
 
 
 
 
  
Table 42: Difference between the detailed wheeze phenotypes for the gene expression of Dectin1 on ΔCT level 
within the different stimuli (unstimulated; PHA and LpA) and number of available samples (n)   
 
haahkahlkj 
 
 
 
Dectin1 n median 95% CI 
HC M 26 11.82 11.28;13.07 
 PHA 25 13.23 12.55;14.50 
LpA 26 11.54 11.07;13.05 
PMT M 4 10.56 5.77;15.48 
 PHA 4 11.14 8.64;13.49 
LPA 3 10.89 6.62;14.42 
LOM M 9 10.19 8.97;13.14 
 PHA 10 11.95 10.49;14.73 
LpA 9 11.80 10.55;15.37 
EVW M 17 12.18 10.67;12.78 
 PHA 18 13.83 12.56;14.89 
LPA 18 11.75 11.09;13.23 
PVW M 11 11.57 11.04;13.76 
 PHA 11 13.89 12.26;15.81 
LpA 10 12.49 11.67;13.06 
LOVW M 6 11.87 9.43;14.37 
 PHA 5 17.19 10.60;21.60 
LPA 5 12.22 9.91;14.32 
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4.3.7.7. Dectin2 (CLEC6A)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: Difference between the detailed wheeze phenotypes for the gene expression of Dectin2. 
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
For Dectin2, the detailed analysis showed a trend to a lower gene expression in media in 
PVW compared with HC (p-value=0.099) and after PHA stimulation in EVW compared 
with PMT (p-value=0.081). These findings must be seen in context with the high non-
detection rate meaning a limited informative value. 
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Table 43: Difference between the detailed wheeze phenotypes for the gene expression of Dectin2 on ΔCT level 
within the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
Dectin2 n median 95% CI 
HC M 24 20.55 19.27;21.85 
 PHA 24 18.28 17.59;20.52 
LpA 25 15.71 15.15;17.84 
PMT M 2 19.54 18.96;20.11 
 PHA 4 16.42 15.06;18.38 
LPA 3 15.86 14.76;16.64 
LOM M 9 21.69 19.10;22.80 
 PHA 8 17.77 15.29;22.20 
LpA 9 17.58 15.95;20.82 
EVW M 18 21.26 18.94;22.19 
 PHA 18 18.65 17.85;21.19 
LPA 17 16.19 15.54;17.23 
PVW M 11 23.43 20.89;23.75 
 PHA 11 19.12 16.88;20.92 
LpA 10 17.40 15.69;18.29 
LOVW M 6 18.99 15.04;23.93 
 PHA 5 20.63 17.00;23.53 
LPA 5 16.04 12.04;22.54 
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4.3.7.8. LMP2 
 
 Figure 47: Difference between the detailed wheeze phenotypes for the gene expression of LMP2.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
For LMP2, the detailed analysis showed a significantly lower gene expression in media 
for PVW compared with EVW (p-value=0.014) and a trend to a lower gene expression 
compared with HC (p-value=0.0697) and with LOVW (p-value=0.078). After PHA 
stimulation, there was a significantly higher gene expression in PMT than in HC (p-
value=0.016) and in EVW (p-value=0.033). There also was a trend to a higher gene 
expression compared with LOVW (p-value=0.063). 
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4.3.7.9. LMP7 
 
 
Figure 48: Difference between the detailed wheeze phenotypes for the gene expression of LMP7. 
 p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
Table 44: Difference between the detailed wheeze phenotypes for the gene expression of LMP2 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
LMP2 n median 95% CI 
HC M 26 12.98 12.083.90 
 PHA 26 9.76 9.36;11.24 
LpA 26 10.19 9.25;10.64 
PMT M 4 12.04 7.78;15.61 
 PHA 4 8.06 6.97;8.92 
LPA 3 7.58 4.00;12.58 
LOM M 10 12.68 10.10;16.40 
 PHA 10 9.39 8.10;11.10 
LpA 9 10.49 9.14;12.79 
EVW M 18 11.37 10.92;13.83 
 PHA 18 9.45 8.81;10.94 
LPA 18 9.67 9.13;11.73 
PVW M 11 13.78 12.67;17.13 
 PHA 11 9.18 8.04;10.96 
LpA 10 10.25 9.97;11.19 
LOVW M 6 12.79 10.14;14.54 
 PHA 5 13.76 8.56;15.81 
LPA 5 9.54 7.57;12.51 
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For LMP7, the detailed analysis showed a trend to a higher gene expression following 
LpA stimulation in PMT than in PVW (p-value=0.077). 
 
 
 
 
 
 
 
 
 
 
  
Table 45: Difference between the detailed wheeze phenotypes for the gene expression of LMP7 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
LMP7 n median 95% CI 
HC M 26 12.08 11.58;13.87 
 PHA 26 9.89 9.51;12.13 
LpA 25 10.15 9.43;11.12 
PMT M 4 11.34 6.99;16.74 
 PHA 4 8.61 6.26;11.05 
LPA 3 8.94 5.97;12.45 
LOM M 10 11.32 8.97;16.50 
 PHA 10 9.14 8.04;11.21 
LpA 8 10.73 9.33;12.10 
EVW M 18 13.04 11.81;14.84 
 PHA 17 9.95 9.39;11.76 
LPA 17 10.01 9.38;12.56 
PVW M 11 12.43 11.71;16.73 
 PHA 11 9.26 7.76;12.64 
LpA 10 10.79 10.24;11.82 
LOVW M 6 12.52 10.10;15.28 
 PHA 4 13.14 5.45;20.41 
LPA 5 10.14 7.74;13.21 
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4.3.7.10. NLRP3 
 
 
Figure 49: Difference between the detailed wheeze phenotypes for the gene expression of NLRP3.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
For NLRP3, the detailed analysis showed a higher gene expression in multitrigger 
wheezing over all stimulation conditions. In media, LOM showed a higher gene 
expression compared with PVW (p-value=0.0486) and with EVW (p-value=0.058). PMT 
showed a trend to a higher gene expression than EVW (p-value=0.097). After PHA 
stimulation, both PMT and LOM showed a higher gene expression than HC (p- 
value=0.052 and p- value=0.063), EVW (p- value=0.024 and p- value=0.066), PVW (p- 
value=0.058 and p- value=0.072) and LOVW (p- value=0.057 and p- value=0.036). After 
LpA stimulation, PMT showed a higher gene expression than PVW (p- value=0.014). 
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4.3.7.11. Casp1 
 
 
 Figure 50: Difference between the detailed wheeze phenotypes for the gene expression of Casp1.  
 p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
NLRP3 n median 95% CI 
HC M 26 12.69 12.21;13.57 
 PHA 26 15.26 14.74;16.54 
LpA 26 13.28 12.78;14.38 
PMT M 4 11.71 9.30;14.35 
 PHA 4 14.08 13.57;14.83 
LPA 3 12.74 12.16;13.36 
LOM M 10 11.85 10.31;13.25 
 PHA 10 14.40 12.99;16.32 
LpA 9 13.56 12.57;15.32 
EVW M 18 12.73 12.43;14.53 
 PHA 17 15.56 14.65;16.74 
LPA 18 13.77 12.87;14.83 
PVW M 11 12.89 11.93;16.44 
 PHA 11 15.33 14.46;1.64 
LpA 10 13.96 13.65;14.56 
LOVW M 6 12.42 10.86;13.97 
 PHA 4 18.65 12.74;24.16 
LPA 5 12.85 11.25;15.01 
Table 46: Difference between the detailed wheeze phenotypes for the gene expression of NLRP3 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n)  
75 
 
For Casp1, the detailed analysis showed a lower gene expression in PVW in media 
compared with HC (p-value=0.074), EVW (p-value= 0.041), LOVW (p-value= 0.097) and 
LOM (p-value= 0.084). After PHA stimulation, PMT showed a higher gene expression 
than HC (p-value=0.022) and PVW (p-value= 0.078). LOVW showed a lower gene 
expression compared with HC (p-value=0.091) and EVW (p-value=0.055). After LpA 
stimulation, PMT showed a higher gene expression than PVW (p-value=0.049) and than 
LOM (p-value=0.063). 
  
Table 47: Difference between the detailed wheeze phenotypes for the gene expression of Casp1 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
CASP1 n median 95% CI 
HC M 25 12.52 11.67;13.20 
 PHA 26 11.46 10.95;12.85 
LpA 26 9.96 9.40;11.20 
PMT M 4 11.16 4.90;15.85 
 PHA 4 9.88 6.05;12.58 
LPA 3 9.32 2.29;14.07 
LOM M 10 11.72 9.51;15.41 
 PHA 10 10.94 9.37;14.01 
LpA 9 11.11 9.71;13.88 
EVW M 18 12.07 10.56;13.87 
 PHA 18 11.48 9.82;12.37 
LPA 18 9.74 8.48;11.13 
PVW M 11 13.59 12.21;16.87 
 PHA 11 10.88 9.95;14.06 
LpA 10 10.81 10.05;11.75 
LOVW M 6 12.37 9.05;14.16 
 PHA 5 14.86 9.26;21.99 
LPA 5 9.99 7.74;14.84 
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4.3.7.12. IL-1R1 
 
 
Figure 51: Difference between the detailed wheeze phenotypes for the gene expression of IL1R1.  
p-value:  ≤0.1= #  ≤ 0.05= * ;  ≤ 0.01=** ,≤ 0.005=*** 
 
For IL-1R1, the detailed analysis showed a higher gene expression in multitrigger 
wheezing following PHA stimulation and LpA stimulation. In PHA, PMT showed higher 
gene expression than PVW (p-value=0.017), LOVW (p-value=0 .063), EVW (p-value= 
0.074) and HC (p-value=0.082). LOM showed higher gene expression than PVW (p-
value=0.061) and LOVW (p-value=0.075). After LpA stimulation, PMT showed 
significantly higher gene expression than PVW (p-value=0.007) and a trend to a higher 
gene expression than LOVW (p-value=0.071). In media, PVW showed a trend to a lower 
gene expression than HC (p-value=0.074). 
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Table 48: Difference between the detailed wheeze phenotypes for the gene expression of IL-1R1 on ΔCT level within 
the different stimuli (unstimulated; PHA and LpA) and number of available samples (n) 
  IL-1R1 n median 95% CI 
HC M 25 15.57 14.77;16.93 
 PHA 26 15.02 14.63;16.58 
LpA 26 14.82 13.78;16.13 
PMT M 4 13.47 7.46;21.15 
 PHA 4 13.78 11.82;15.44 
LPA 3 13.05 8.62;16.48 
LOM M 10 15.15 13.00;18.46 
 PHA 10 14.79 13.14;16.64 
LpA 8 14.44 12.54;17.58 
EVW M 18 15.51 14.40;17.48 
 PHA 18 15.80 14.67;17.00 
LPA 18 14.13 13.44;15.65 
PVW M 11 16.52 15.63;19.68 
 PHA 11 16.69 15.20;18.60 
LpA 10 15.59 14.69;16.22 
LOVW M 6 17.30 14.59;19.06 
 PHA 5 20.56 14.09;22.90 
LPA 5 16.46 13.52;18.07 
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4.3.8. Gene expression patterns considering temporal aspects of 
wheezing symptoms 
 
Table 49 shows a general overview of gene expression patterns for the more detailed 
phenotypes. Significant results are marked green (p-value <0,05), trends are marked 
orange (p-value < 0,1). 
Table 49.1: Overview of gene expression patterns for more detailed phenotypes 
 TLR5 
media     PHA      LpA 
TLR7 
media     PHA      LpA 
RIG-I 
media     PHA      LpA 
MDA-5 
media     PHA      LpA 
PMT vs 
PVW 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT vs 
LOVW 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT vs 
EVW 
PMT
↓ 
PMT 
↑ 
PMT 
↓ 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT vs 
HC 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT vs 
LOM 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
LOM vs 
PVW 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM vs 
LOVW 
LOM 
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM 
↑ 
LOM 
↑ 
LOM  
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM vs 
EVW 
LOM
↓ 
LOM 
↑ 
LOM 
↓ 
LOM 
↑ 
LOM 
↓ 
LOM 
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM
↑ 
LOM 
↑ 
LOM 
↓ 
LOM vs 
HC 
LOM 
↑ 
LOM 
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM
↓ 
LOM
↑ 
LOM 
↑ 
LOM 
↓ 
LOM
↑ 
LOM LOM
↓ 
PVW vs 
LOVW 
PVW 
↓ 
PVW
↔ 
PVW
↓ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓  
PVW 
↑ 
PVW 
↓ 
PVW
↑ 
PVW 
↑ 
PVW 
↓ 
PVW vs 
EVW 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW
↑ 
PVW
↓ 
PVW 
↓ 
PVW
↑ 
PVW
↓ 
PVW vs 
HC 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
LOVW 
vs EVW 
LOV 
↑ 
LOV
↑ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV
↓ 
LOV 
↓ 
LOV
↓ 
LOV 
↓ 
LOVW 
vs HC 
LOV 
↑ 
LOV 
↑ 
LOV 
↓ 
LOV 
↑ 
LOV 
↓ 
LOV 
↓ 
LOV
↑ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV 
↓ 
LOV
↓ 
EVW vs 
HC 
EV
W ↑ 
EV
W ↓ 
EV
W ↑ 
EV
W ↑ 
EV
W↑ 
EV
W ↑ 
EV
W ↑ 
EV
W ↓ 
EV
W ↑ 
EV
W ↑ 
EV
W ↓ 
EW
V ↑ 
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Table 48.2: Overview of gene expression patterns for more detailed phenotypes 
 Mincle 
media     PHA      LpA 
Dectin1 
media     PHA      LpA 
Dectin2 
media     PHA      LpA 
LMP2 
media     PHA      LpA 
PMT vs 
PVW 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT vs 
LOVW 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT vs 
EVW 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↓ 
PMT 
↑ 
PMT
↑ 
PMT vs 
HC 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↓ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT vs 
LOM 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↓ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
LOM vs 
PVW 
LOM 
↑ 
LOM 
↓ 
LOM
↓ 
LOM 
↑ 
LOM 
↑ 
LOM
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM 
↑ 
LOM
↓ 
LOM 
↓ 
LOM vs 
LOVW 
LOM
↓ 
LOM 
↑ 
LOM
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM 
↑ 
LOM
↓ 
LOM
↑ 
LOM 
↑ 
LOM
↓ 
LOM vs 
EVW 
LOM
↓ 
LOM
↑ 
LOM
↓ 
LOM 
↑ 
LOM 
↑ 
LOM
↓ 
LOM 
↓ 
LOM 
↑ 
LOM
↓ 
LOM 
↓ 
LOM 
↑ 
LOM
↓ 
LOM vs 
HC 
LOM 
↓ 
LOM
↓ 
LOM 
↓ 
LOM 
↑ 
LOM
↑ 
LOM
↓ 
LOM 
↓ 
LOM 
↓ 
LOM
↓ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
PVW vs 
LOVW 
PVW
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↑ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW
↓ 
PVW
↑ 
PVW 
↓ 
PVW vs 
EVW 
PVW
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW 
↓ 
PVW
↓ 
PVW
↓ 
PVW
↓ 
PVW 
↓ 
PVW 
↑ 
PVW 
↓ 
PVW vs 
HC 
PVW
↓ 
PVW 
↓ 
PVW 
↓ 
PVW
↑ 
PVW 
↓ 
PVW 
↓ 
PVW
↓ 
PVW 
↓ 
PVW
↓ 
PVW
↓ 
PVW 
↑ 
PVW
↓ 
LOVW 
vs EVW 
LOV 
↑ 
LOV
↓ 
LOV
↓ 
LOV 
↑ 
LOV 
↓ 
LOV 
↓ 
LOV 
↑  
LOV
↓ 
LOV
↑ 
LOV 
↓ 
LOV 
↓ 
LOV 
↑ 
LOVW 
vs HC 
LOV
↑ 
LOV 
↓ 
LOV
↑ 
LOV
↓ 
LOV 
↓ 
LOV 
↓ 
LOV 
↑ 
LOV
↓ 
LOV 
↓ 
LOV
↑  
LOV
↓ 
LOV
↑ 
EVW vs 
HC 
EV
W ↑ 
EV
W ↓ 
EV
W ↑ 
EV
W ↓ 
EV
W ↓ 
EV
W ↓ 
EV
W ↓ 
EV
W ↓ 
EV
W ↓ 
EV
W ↑ 
EV
W ↑ 
EV
W ↑ 
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Table 48.3: Overview of gene expression patterns for more detailed phenotypes 
 LMP7 
media     PHA      LpA 
NLRP3 
media     PHA      LpA 
Casp1 
media     PHA      LpA 
IL-1R1 
media     PHA      LpA 
PMT vs 
PVW 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT vs 
LOVW 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT vs 
EVW 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT vs 
HC 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT 
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT vs 
LOM 
PMT
↓ 
PMT
↑ 
PMT
↑ 
PMT 
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑  
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
PMT
↑ 
LOM vs 
PVW 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM 
↑ 
LOM
↑ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM
↑ 
LOM
↑ 
LOM 
↑ 
LOM
↑ 
LOM vs 
LOVW 
LOM 
↑ 
LOM
↑ 
LOM 
↓ 
LOM
↑ 
LOM
↑ 
LOM 
↓ 
LOM 
↑ 
LOM 
↑ 
LOM 
↓ 
LOM
↑ 
LOM
↑ 
LOM
↑ 
LOM vs 
EVW 
LOM 
↑ 
LOM
↑ 
LOM 
↓ 
LOM
↑ 
LOM
↑ 
LOM
↑ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM vs 
HC 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM
↑ 
LOM
↑ 
LOM
↓ 
LOM 
↑ 
LOM
↑ 
LOM 
↑ 
PVW vs 
LOVW 
PVW
↑ 
PVW
↑ 
PVW
↓ 
PVW
↓ 
PVW
↑ 
PVW
↓ 
PVW 
↓ 
PVW
↑ 
PVW 
↑ 
PVW
↑ 
PVW 
↑ 
PVW
↑ 
PVW vs 
EVW 
PVW
↑ 
PVW
↑ 
PVW 
↓ 
PVW
↓ 
PVW
↑ 
PVW
↓ 
PVW 
↓ 
PVW
↑ 
PVW 
↓ 
PVW 
↓ 
PVW 
↓ 
PVW
↓ 
PVW vs 
HC 
PVW
↓ 
PVW
↑ 
PVW
↓ 
PVW
↓ 
PVW
↓ 
PVW
↓ 
PVW
↓ 
PVW
↑ 
PVW
↓ 
PVW
↓ 
PVW
↓ 
PVW 
↓ 
LOVW 
vs EVW 
LOV
↑ 
LOV
↓ 
LOV
↓ 
LOV
↑ 
LOV
↓ 
LOV
↑ 
LOV
↓ 
LOV
↓ 
LOV
↓ 
LOV 
↓  
LOV
↓ 
LOV
↓ 
LOVW 
vs HC 
LOV
↓ 
LOV
↓ 
LOV 
↑ 
LOV
↑ 
LOV
↓ 
LOV
↑ 
LOV
↑ 
LOV
↓ 
LOV
↓ 
LOV
↓ 
LOV
↓ 
LOV
↓ 
EVW vs 
HC 
EV
W ↓ 
EV
W ↓ 
EV
W ↑ 
EV
W ↓ 
EV
W ↓ 
EV
W ↓ 
EV
W ↑ 
EV
W ↓ 
EV
W ↑ 
EV
W ↑ 
EV
W ↓ 
EV
W ↑ 
 
4.3.9. Added value of the more detailed phenotype analysis 
 
The more detailed phenotype analysis revealed that children with persistent symptoms 
most strongly contributed to the found gene expression differences. 
This effect could be seen especially for persistent multitrigger wheeze. After PHA 
stimulation, children with persistent multitrigger wheeze showed a significant 
upregulation of the gene expression of MDA-5, LMP2, NLRP3, Casp1 and IL-1R1. For 
Mincle, NLRP3, Casp1 and IL-1R1, this was also detectable after LpA stimulation. 
In parallel, it was children with persistent viral wheeze who showed the most significant 
reduction in gene expression among all children with viral wheeze. This downregulation 
was most strongly detectable for MDA-5, LMP2 and Casp1 in unstimulated condition 
and for TLR7 and Mincle after LpA stimulation. 
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In summary, the more detailed phenotype analysis allowed a more in-depth insight into 
the importance of the temporal aspect of the wheezing symptoms. However, these 
findings have to be interpreted with caution as the sample size decreases within the 
subgroups.  
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5. DISCUSSION 
 
5.1. Main findings 
 
(1) The expression of most of the tested genes of the innate immune system, the 
inflammasome and the immunoproteasome increased significantly after stimulation of 
cord blood mononuclear cells with PHA and LpA. Interestingly, Dectin1 and NLRP3 
showed a significant downregulation after stimulation with PHA. 
(2) Said genes differed significantly between asymptomatic newborns according to their 
subsequent wheeze phenotype. Healthy controls showed a different gene expression 
compared to children with multitrigger wheeze and children with persistent or late onset 
viral wheeze but not compared to children with early viral wheeze. 
(3a) Within the phenotype comparison, children with multitrigger wheeze showed the 
highest gene expression overall and children with viral wheeze the lowest compared with 
the other phenotypes. Interestingly, the gene expression of healthy controls was ranked 
in between the symptomatic phenotypes indicating that subsequently healthy controls 
might have a more controlled immune balance than children with symptoms in the first 
years of life. 
(3b) The more detailed phenotype analysis including a temporal pattern of wheeze 
showed that persistent multitrigger wheeze most strongly induced the upregulation of 
gene expression in children with multitrigger wheeze.  
 (4) Multitrigger wheeze and viral wheeze differed most clearly with increased gene 
expression of TLR5, Dectin1, NLRP3 and IL-1R1 in children with multitrigger wheeze 
compared to a decreased gene expression of TLR7, MDA-5 and IL-1R1 in children with 
viral wheeze. This indicated different disease entities, characterized by distinct immune 
regulation, of the wheeze phenotypes.  
(5) Some pathways, especially the NLRP3/IL-1R1 axis, are already regulated differently 
at birth which may implicate a genetic or epigenetic component for the different 
phenotypes, especially persistent multitrigger wheeze.  
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5.1.1. Differences in gene expression and phenotype characteristics   
5.1.1.1. Multitrigger wheeze is characterized by an upregulation of gene 
expression 
The group comparison of the wheeze phenotypes revealed that children classified as 
multitrigger wheezers showed an overall upregulation of the examined genes. Especially 
genes related to the inflammasome/IL-1R1 axis were consistently increased in children 
with multitrigger wheeze with this effect being significant for NLRP3 and IL-1R1. It has 
been shown previously that the NLRP3 inflammasome together with Casp1 is 
upregulated in neutrophilic asthma in adults [71]. In this project, an upregulation of these 
genes was already detectable at birth (see Figure 52).  
At birth, children with subsequent multitrigger wheeze showed the highest gene 
expression after PHA stimulation. This was not only shown for the inflammasome/IL-
1R1 axis but also for several genes encoding for PPRs (TLR5, TLR7, and Dectin1).  
This increased expression could play an important role for the development of wheeze 
symptoms during immune maturation. The impact of other PPRs on inflammation and 
asthma development have already been shown [53, 76].   
The upregulation of gene expression after PHA stimulation at birth in children with future 
multitrigger wheeze highlights the strong susceptibility of children with multitrigger 
wheeze to possible triggers. This may be a hint of an immune imbalance or potential 
deficiency in control mechanisms which leads to exuberant activation already at a time 
when the child is clinically asymptomatic. Subsequently, these children develop 
symptoms of wheeze in pre-school age.  
In summary, multitrigger wheeze was characterized by an upregulation of gene 
expression encoding for PRRs, inflammasome and the IL-1R1 axis together with 
upregulated immunoproteasome genes. These results may point out a genetic component 
for the development of a multitrigger wheeze phenotype in childhood. 
 
5.1.1.2. Viral wheeze is characterized by a downregulation of gene 
expression 
In contrast, children with future persistent or late onset viral wheeze presented an overall 
downregulation of gene expression at birth compared with the other phenotypes. 
Interestingly, the downregulation was most strongly observed after stimulation with 
either PHA or LpA. After PHA stimulation, IL-1R1 was significantly downregulated 
compared with healthy controls. The gene expression only showed a trend towards a 
downregulation under unstimulated conditions (MDA-5 and IL-1R1) which could be due 
to the limited sample size. Additionally, there was a downregulation of PRRs (TLR7, 
MDA-5, and Mincle) detectable after LpA stimulation.  
This might highlight that the imbalance of the immune system of those children could be 
triggered by environmental factors acting as a ‘second hit’.  
This may indicate that children presenting with persistent and/or late onset viral wheeze 
might be unable to react adequately to immune stimuli due to deficiency in specific innate 
immune system pathways. This can result in an inefficiency to respond to viral infections 
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leading to a longer and more severe infection period presenting with clinical symptoms 
of wheeze. In accordance with this finding, it has been shown that among asthmatic 
children with virus-triggered exacerbations those prone to viral re-infection show an 
impaired anti-viral response with altered PRR function [77]. Childhood viral infections 
with persistent wheeze are known to be a risk factor for asthma development [78]. 
These findings indicate the existence of a host factor explaining differences of symptom 
features such as vulnerability to or duration of wheeze. This is supported by another study 
that showed that the duration of wheeze symptoms during an infection is independent of 
the microbial trigger [79]. In summary, symptoms of children with persistent and/or late 
onset viral wheeze could be triggered by environmental factors revealing the deficiency 
of specific innate immune pathways that were detectable already at birth. This is in line 
with findings from Spycher et al. that indicate different disease entities for children with 
multitrigger wheeze and children with early viral wheeze [80].  
 
5.1.1.3. Early viral wheeze and healthy controls feature a similar gene 
expression pattern 
 
There was no statistically significant difference between early viral wheeze and healthy 
controls detectable. This may indicate that children with future early viral wheeze with 
no complications such as hospitalization and healthy children have similar immune 
regulation at birth. The children with early viral wheeze may however react with mild 
self-limiting symptoms. Therefore, children with early viral wheeze and balanced 
immune regulation at birth may have a rather small potential risk for asthma development. 
This finding is supported by other studies that distinguish between children with an 
elevated asthma risk and children with transient early wheeze [81, 82]. In addition, it has 
been shown that children wheezing only within the first 3 years of life were as unlikely 
to show wheezing symptoms later in life as healthy controls [83, 84]. Thus, for this group 
of children it may actually be very informative to have early life immune regulation data 
available. Intense treatment could be potentially avoided, and conversely rather be 
applied to children with future multitrigger wheeze. 
Healthy controls, defined by no symptoms at any age of follow-up, showed a gene 
expression in range between children with multitrigger wheeze and children with viral 
wheeze. This finding might indicate that these children had an appropriate immune 
balance at birth followed by no development of symptoms later in life. 
This supports the idea that both an exaggerated immune response found in multitrigger 
wheeze and a decreased gene expression found in persistent and/or late onset wheeze 
results in a dysfunction contributing to the development of childhood wheeze. This 
indicates a limited range of healthy immune regulatory propensity already at birth.  
 
To date, many approaches have been established in order to personalize treatment 
strategies in young children with wheeze and asthma and to optimize the individual 
treatment response. This is important when trying to avoid both overtreatment and 
exacerbations. The prediction of asthma development in wheezing infants has become of 
growing interest as there is evidence for the heterogeneity of this patient group [12] 
leading to remaining treatment gaps [85].  
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In this project, focus has been put on differences in the gene expression of pathways 
related to the innate immune system detected in cord blood.  
These genes include the NFκB signalling pathway with its downregulation known to have 
a therapeutic effect on asthma [40].  It is influenced by – among others – PRRs, the 
inflammasome and the immunoproteasome.    
Those genes were chosen for analysis as they are likely to have influence on the pathology 
of asthma development. TLRs are known to be potential risk genes for asthma [51], genes 
of the immunoproteasome and the gene encoding for Mincle – a CLR- are known to 
influence the TH cell response in both human and mice [58, 65]. Genes of the NLRP3 
inflammasome /IL-1R1 axis modulate airway inflammation [68] and are associated with 
asthma in human [71, 73] and have become of recent interest as a therapeutic target in 
allergic diseases [86]. 
The found upregulation of gene expression for said genes – especially the NLRP3/IL-
1R1 axis – in children with multitrigger wheeze compared to the other phenotypes 
underlines the mentioned heterogeneity of asthma pathology. In this context, those 
children might be at higher risk for asthma development and could be filtered out for 
research like intervention studies. 
Additionally, early viral wheeze was not associated with any significant differences in 
gene expression compared with healthy controls. This might indicate that those children 
may not benefit from an intensive treatment strategy as they are likely to ‘outgrow’ their 
symptoms.  This is in line with other findings indicating that children with multitrigger 
wheeze benefit from a continuous use of medication whereas intermittent treatment 
should be applied to children with early viral wheeze [87]. 
Further research on the prediction of asthma development of wheezing infants could 
contribute to avoiding overtreatment in this subgroup. 
We found differences in the expression of genes related to the pathology of asthma 
already at birth. However, due to the limited sample size, further research is urgently 
needed to confirm and better understand those findings. The on-going follow up at age 
10 years of the children analyzed in this project will also add important information of 
future symptom development of the different phenotypes. 
 
 
  
Figure 52: Visualization of the hypothesized endotype characteristics found in this project 
 
86 
 
5.1.2. Differences in gene expression considering persistency of 
symptoms  
The more detailed phenotype analysis included the temporal pattern of wheeze symptoms 
leading to smaller subgroups of children within multitrigger wheeze and viral wheeze. 
Therefore, these findings have to be interpreted with caution. They were classified into 
either ‘persistent’ or ‘late onset’ viral or multitrigger wheeze, respectively.  
 
Classification of children with multitrigger wheeze into those with persistent or late onset 
multitrigger wheeze unmasked the strongest upregulation in children with persistent 
multitrigger wheeze.  
In contrast to the phenotype analysis in the four larger groups, children with persistent 
multitrigger wheeze did not show statistically significant differences in gene expression 
without immune stimulation as compared to other subgroups. However, the upregulation 
of the gene expression in children with persistent multitrigger wheeze after PHA 
stimulation was more strongly detectable even though the number of samples decreased 
from 14 to 4. This was detectable for all analyzed genetic pathways, including the PRRs 
(TLR5, TLR7, MDA-5 and Dectin1), the immunoproteasome (LMP2) and the 
inflammasome/IL-1R1 axis. This indicates that the immune system of children with 
subsequent persistent multitrigger wheeze shows an exaggerated response upon 
stimulation right after birth. This was also detectable after LpA stimulation for Mincle, 
NLRP3, Casp1 and IL-1R1. 
Thus, children with persistent multitrigger wheeze may have a predisposition at birth 
which is visible following immune activation and may lead to uncontrolled immune 
regulation when exposed to triggers subsequently. This may in the long-term result in an 
increased risk for chronic wheeze symptoms and potentially the development of 
childhood asthma later in life. This is in line with results from Hallberg et al who found 
that early persistent wheeze was associated with the strongest lung impairment at age 16 
[88]. Yet, the subgroup of children is very small, and these findings need to be replicated 
in larger studies. If this can be confirmed in other studies, it may be possible to identify 
these children already early in life and either monitor them more closely in case of 
symptoms or select those for potential early intervention studies.  
Gene expression of children with late onset multitrigger wheeze showed some similarities 
to gene expression pattern of those with persistent multitrigger wheeze but differed in 
other points.  
Similar to persistent multitrigger wheezers, children with late onset multitrigger wheeze 
showed an upregulation of NLRP3 and the PRRs TLR5 and TLR7 after PHA stimulation. 
This indicates that these phenotypes share some features in terms of increased innate 
immune responses. However, children with late onset multitrigger wheeze showed a 
downregulation after LpA stimulation for TLR7 and Mincle explaining why there was no 
difference detectable for the more unspecific phenotype analysis in larger groups. 
Additionally, this shows that the two phenotypes are different, which could be a hint that 
children with late onset multitrigger wheeze may better compensate the assumed immune 
imbalance resulting in later onset of symptoms. 
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Subclassification of children with viral wheeze into those with persistent and late onset 
viral wheeze indicated strong downregulation of gene expression in persistent viral 
wheezers.  
Interestingly, the difference in gene expression was most strongly detectable between 
children with persistent viral wheeze and early viral wheeze. There was a significant 
downregulation in children with persistent viral wheeze for TLR7 and Mincle after LpA 
stimulation.  
Additionally, RIG-I, LMP2 and Casp1also showed a downregulation compared to early 
viral wheeze in unstimulated conditions.  
This might indicate a genetic background or different susceptibility for the persistency of 
wheezing symptoms in a viral infection. In contrast to children with early viral wheeze 
(symptoms only up to age 3 years), children with persistent viral wheeze (symptoms at 
both age 3 and age 6 years) might feature an unbalanced immune response resulting in 
persistency of symptoms. This may put those children at a higher risk for asthma 
development as they are more likely to have recurrent symptoms. Recurrence of 
symptoms is known to be a risk factor for asthma development and therefore is one 
criterion of the Asthma Predictive Index [89]. This index based upon simple clinical 
criteria, like parents diagnosed with asthma or evidence of sensitization, is used to 
determine which children under the age of 3 years are likely to develop asthma later in 
life[90]. In line with these findings, it has been shown previously that children with 
persistent wheeze are more likely to develop allergies and asthma later in life [84]. 
 
Children with late onset viral wheeze showed a trend towards increased gene expression 
for Mincle, LMP2 and Casp1 compared to persistent viral wheeze. These findings of 
differences between persistent and late onset viral wheeze, although for a small number 
of children, may explain less findings in the analyses of the larger, more unspecific 
phenotype analysis.  
 
In summary, both children with persistent multitrigger wheeze and children with 
persistent viral wheeze showed an aberrant gene expression after immune system 
stimulation. Increased gene expression of NLRP3/IL-1R1pathways in children with 
persistent multitrigger wheeze might reveal a genetic risk factor for developing persistent 
symptoms. However, the pathophysiology of asthma development is complex with many 
contributing factors.  
Children with persistent viral wheeze showed decreased gene expression already at birth 
potentially predisposing the children to an inefficient response to viral infections. This 
may explain why those children continuously have viral-induced wheeze later in life.  
Taken together, the more detailed phenotype analysis revealed that both phenotypes with 
persistent symptoms showed highly differing gene expression compared to the other 
phenotypes. Persistency of symptoms seems to be linked with the strongest up- and 
downregulation of gene expression.  
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5.2. Confounder analysis and multiple testing 
As there was a reasonable positive correlation (average correlation coefficient around 0.6; 
see page 36) between gene expressions, a strict multiple comparison’s adjustment as 
Bonferroni would be overly conservative. Acknowledging the explorative character of 
this project and due to the restricted sample size caused by limited availability of the 
human blood samples we waived any correction. For that reason, there was no adjustment 
for multiple testing performed.   
The analysis of the different phenotypes for possible confounders revealed significant 
differences regarding maternal asthma and maternal school education. These differences 
were significant for maternal asthma when comparing healthy children (0.0% maternal 
asthma) and children with persistent or late onset viral wheeze (22.2% maternal asthma). 
For maternal education, there was a statistically significant difference when comparing 
children with multitrigger wheeze (mean=13 years of maternal education) and children 
with early viral wheeze (mean= 16 years of maternal education). Therefore, a possible 
effect of both maternal asthma and maternal education on the gene expression was 
calculated by grouping the children according to the maternal asthma or maternal 
education status.  
There was no statistically significant difference in the gene expression between the two 
groups for maternal asthma (maternal asthma yes/no). This finding indicates that maternal 
asthma has no direct influence on the gene expression of the analyzed genes resulting in 
no need to adjust for maternal asthma. 
However, for maternal school education, three findings were significant: LMP2, LMP 7 
and NLRP3 (all after PHA stimulation). Therefore, the significant findings within these 
genes were recalculated stratified for maternal school years. The analysis showed that the 
overall upregulation of gene expression in children with multitrigger wheeze remained 
unchanged for children with 9-13 years of maternal school education. However, for 
children with late onset multitrigger wheeze and 16 years of maternal education a lower 
gene expression of NLRP3 was indicated compared with the other phenotypes. This 
indicated downregulation was not statistically significant (see page 120) with p-values 
ranged from 0.96 and 0.78. For this reason, no general adjustment for maternal education 
was performed in this project. However, maternal education is known as a possible 
confounder for asthma development [91] even though its influence was negligible in this 
project. 
 
5.3. Evaluation of methods 
CBMC stimulation showed the strongest effect after LpA stimulation (see page 37). LpA 
is a potent stimulus of the innate immune system as its primary binding partners are 
monocytes, macrophages and neutrophils [92]. LpA triggers a rapid innate immune 
response with the release of, among others, IL-1, IL-8, leukotrienes and prostaglandins. 
Taken together, LpA stimulation mimics the cell signalling processes following the 
activation of the innate immune system [93] by bacteria. 
This process is mediated – among others – by TLRs. LpA is known to potentially activate 
TLR4 and it has recently been shown that this process is modulated by NFκB [94].  
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Interestingly, most significant findings could be seen after PHA stimulation. PHA is 
known to stimulate T cell proliferation [95] and thereby is an activator of the adaptive 
immune system. However, it could be possible that PHA as a very potent stimulus might 
also have an indirect effect on innate immune activation. That might explain the 
divergence between PHA as a known T cell stimulus and finding the most effects on 
expression of genes related to the innate immune system after this stimulation.  
Measuring gene expression in cord blood is a non-invasive method at the earliest time 
point available. This raises a lot of opportunities especially when it comes to finding early 
risk factors in order to filter out those children who would benefit from an early treatment 
strategy. Of course, further research is needed to define said early risk factors. 
The qRT-PCR is a very specific and at the same time very sensitive method to detect even 
small differences in mRNA expression. Measuring cDNA levels, meaning indirect 
measurement of mRNA levels, cannot depict the actual translation product activity in the 
cell. However, it can help to find potential candidate gene and related pathways for further 
research. 
Additionally, the measured differences in gene expression might hold the potential to be 
used as a predictive biomarker regardless of the actual involvement of these genes in the 
disease’s pathogenesis.  
 
5.4. Evaluation of the PAULINA/PAULCHEN birth cohort  
The PAULINA/PAULCHEN cohort is an in depth described birth cohort with detailed 
information at inclusion about both the child and the parents. Additionally, it provides 
detailled follow-up information at both age 3 years and age 6 years with current ongoing 
follow-up with 10 years of age. This information offers the opportunity to further 
investigate the children for their consistency in the development of the defined 
phenotypes. The quality of patient recruitment was assured by the consistent application 
of inclusion and exclusion criteria. The number of children developing symptoms was in 
accordance with the wheeze prevalence in children that can range between 15 percent and 
40 percent depending on the analyzed population [96, 97]. As the PAULINA study 
population was recruited based upon random selection, this led to a limited sample size. 
Due to this availability of limited samples from children presenting with symptoms, the 
found gene expression differences between the different wheeze phenotypes need to be 
further investigated.  
However, it is highly interesting that even with this small number of children there were 
significant differences between the phenotypes detectable. Nevertheless, as the number 
of children in the subgroups decrease, replication in larger numbers and potentially 
including functional studies is required.  
One facet of note is that the information is based on questionnaire assessment. While 
some studies are critical regarding reliability [98], a number of epidemiological studies 
showed that questionnaire-based information was reflecting clinical phenotypes reliably 
[83].  
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5.5. Conclusion 
In this project, there was a difference in the gene expressions of children with defined 
wheeze phenotypes detectable at birth. Showing a signature of childhood wheeze 
phenotypes on mRNA level, these results may contribute to finding potential new 
biomarkers for the prediction of asthma development following childhood wheeze. This 
is especially important as half of preschool children show wheezing symptoms at least 
once and a third of those is likely to develop asthma [97]. This highlights the necessity to 
filter out those children at risk in order to provide best treatment or close follow-up and 
at the same time to avoid overtreatment for those children that will most likely outgrow 
their symptoms. 
In this project, insights into novel gene regulation mechanisms revealed potential new 
biomarkers for the prediction of childhood wheeze. As a potential new biomarker should 
be assessed as easily as possible in the clinic, genes with a different expression between 
the phenotypes under unstimulated conditions seem most promising. This has the 
advantage that no cell culturing is necessary in addition to the advantage of a non-invasive 
method of sample collection provided by cord blood. In order to distinguish between the 
wheeze phenotypes and to assess the personal asthma risk later in life, it seems highly 
interesting to further investigate the role of the inflammasome/IL-1R1 axis. In this 
project, the gene expression of NLRP3, Casp1 and IL-1R1 differed significantly between 
the wheeze phenotypes and, which is especially important, differed from the gene 
expression of healthy controls. Consequently, considering those genes as potential 
biomarkers for the prediction of childhood wheeze might be a possibility to assess the 
personal risk allowing a more personalized treatment strategy. However, further research 
is needed in order to assess the potential of these genes as predictive biomarkers of 
childhood wheeze.  
 
5.6. Outlook 
To further investigate the symptom development of the children and to address which 
actually develop to a consistent asthma phenotype or outgrow their symptoms, the 
ongoing follow up at age of 10 years will help to answer these questions.  
Additionally, it seems highly interesting to determine which cells actually contribute to 
the upregulation of the gene expression. This could be further analyzed by isolating the 
immune cells in order to get more insight into the role of the different cell subtypes. 
To assure reproducibility, it would be interesting to confirm these findings in another 
birth cohort.  
Due to the limited sample size leading to small numbers of children especially in the 
subgroups considering the temporal aspect of wheeze, replication in a larger cohort with 
more children is necessary.    
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6. SUMMARY 
Childhood wheeze is very common with a prevalence up to 30%, depending on study 
design and phenotype definition [99]. However, the clinical outcome of children 
wheezing within the first years of life varies widely with some children developing 
asthma later in life and others outgrowing their symptoms. Therefore, the necessity of 
grouping those children in either high-risk or low-risk for complications later in life in 
order to prevent both under- and overtreatment has increased over the past decades. One 
promising approach is endotyping childhood wheeze meaning evaluating the risk 
according to underlying molecular mechanisms leading to new biomarkers for the 
prediction of childhood wheeze. 
In this project, genes related to the innate immune system and to the NFĸB signalling 
pathway were analyzed for differences in expression on RNA level. We hypothesized that 
the gene expression would differ between children with multitrigger wheeze, early viral 
wheeze, late onset/persistent viral wheeze and healthy controls. 
Genes related to the innate immune system and to the NFĸB signalling pathway were 
chosen upon their relevance for asthma based on literature and upon preliminary 
experiments of our work group. 
In order to measure the gene expression at the earliest time point available, cord blood 
mononuclear cells (CBMCs) from children of the PAULINA/PAULCHEN birth cohort 
[3, 74] were stimulated with either PHA or LpA and then analyzed by performing 
quantitative real-time PCR. 
In the PAULINA/PAULCHEN birth cohort, n=283 children were recruited between 2004 
and 2008 with a detailed questionnaire at birth, at age 3 years, at age 6 years and an 
ongoing follow up until today. Based on the questionnaires, a subsample of n=76 children 
were classified into healthy controls, multitrigger wheeze, early viral wheeze or late 
onset/persistent viral wheeze and gene expression was measured on RNA level by 
performing quantitative real-time PCR of cDNA. 
The phenotype comparison revealed that children with multitrigger wheeze showed the 
highest gene expression overall and children with viral wheeze the lowest compared with 
the other phenotypes. This effect was most strongly detectable for genes related to the 
inflammasome/IL-1R1 axis (NLRP3, Casp1, IL-1R1) and remained statistically 
significant even when analyzing more detailed phenotypes taking into account the 
temporal pattern of wheeze. Even though the number of samples per group decreased, the 
differences were still statistically detectable indicating strong effects. Additionally, 
children with persistency of symptoms showed a more differing gene expression from 
healthy controls than those with late onset symptoms.  
In this project, some candidate genes with the potential of new biomarkers for the 
predication of childhood wheeze were identified. Further analysis including the 
information of the age 10 years follow up and a more detailed understanding of the 
involved cell types together with the confirmation in another birth cohort is needed to 
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fully understand the potential of these candidate genes as new predictive biomarkers for 
childhood wheeze. 
7. ZUSAMMENFASSUNG 
Pfeifen oder Giemen bei der Ausatmung (sog. wheeze) in der Kindheit sind ein häufig 
auftretendes Symptom mit einer Prävalenz von bis zu 30% [99], je nach betrachteter 
Population. Jedoch unterscheidet sich das spätere klinische Bild der Kinder mit Pfeifen 
oder Giemen sehr deutlich: manche dieser Kinder entwickeln im späteren Leben Asthma 
und bei anderen Kindern verschwinden die Symptome mit zunehmendem Alter komplett. 
Aus diesem Grund ist die Notwendigkeit, diese Kinder nach hohem beziehungsweise 
niedrigem Asthmarisiko einzuteilen über die letzten Jahre enorm gestiegen, gerade im 
Hinblick darauf, sowohl eine Überbehandlung als auch eine medizinische 
Unterversorgung zu verhindern. Ein vielversprechender Ansatz für solch eine Einteilung 
ist die Endotypisierung dieser Kinder. Dabei wird das Asthmarisiko mit Hilfe der 
zugrundeliegenden molekularen Mechanismen ermittelt, was zu sogenannten 
Biomarkern für die Prädiktion von kindlichen Atemgeräuschen und deren weiteren 
Verlauf führen kann. 
In dieser Arbeit wurden Gene, die mit dem angeborenen Immunsystem sowie dem NFĸB 
Signalweg assoziiert sind, auf Unterschiede in der Expression auf RNA Level untersucht 
um mögliche neue Biomarker zu identifizieren. Die Hypothese lautete, dass sich die 
Genexpression von Kindern mit Pfeifen und Giemen (sog. wheeze), die durch mehrere 
Faktoren ausgelöst werden (multitrigger wheeze), solchen Kindern, die früh im Leben im 
Virusinfekt Atemgeräusche zeigten (early viral wheeze), Kindern mit Atemgeräuschen 
im Virusinfekt, die persistieren oder im späteren Leben auftreten (persistent or late onset 
viral wheeze), und gesunden Kontrollen voneinander unterscheiden. 
Die Genauswahl erfolgte anhand der aktuellen Literatur sowie auf Grundlage von 
Vorarbeiten aus der Arbeitsgruppe. Um die Genexpression zu einem möglichst frühen 
Zeitpunkt im Leben zu messen, wurden Nabelschnurblutzellen (CBMCs) von Kindern 
aus der PAULINA/PAULCHEN Geburtskohorte [3, 74] entweder mit PHA oder LpA 
stimuliert und anschließend die Genexpression mit Hilfe von quantitativer real-time PCR 
untersucht. 
Für die PAULINA/PAULCHEN Geburtskohorte wurden n=283 Kinder im Zeitraum von 
2004 bis 2008 in München und Umgebung rekrutiert. Die Rekrutierung und die spätere 
Nachverfolgung beinhalteten einen detaillierten Fragebogen bei Einschluss, nach 3 
Jahren, nach 6 Jahren und aktuell läuft die Nachbereitung nach 10 Jahren. Mit den 
Fragebögen als Grundlage wurde eine Untergruppe von n=76 Kindern in die 
verschiedenen Phänotypen (multitrigger wheeze, early viral wheeze, persistent/late onset 
viral wheeze und gesunde Kontrollen) eingeteilt und deren Genexpression auf RNA level 
mit Hilfe von quantitativer real-time PCR der cDNA analysiert. 
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Der Vergleich der unterschiedlichen Phänotypen zeigte, dass Kinder mit multitrigger 
wheeze einen generellen Anstieg der Genexpression zeigten, wohingegen Kinder mit 
persistent/late onset viral wheeze durch eine generelle Reduktion gekennzeichnet waren. 
Dieser Effekt war am stärksten ausgeprägt für Gene, die mit der Inflammasom/IL-1R1 
Achse assoziiert sind (NLRP3, Casp1 und IL-1R1), und blieb auch bei einer feineren 
Aufteilung der Phänotypen, die den zeitlichen Verlauf der Symptome berücksichtigte, 
erhalten. Obwohl dadurch die Anzahl der Kinder pro Gruppe sank, blieben die 
Unterschiede in der Genexpression nachweisbar, was auf starke Effekte schließen lässt. 
Zusätzlich stellte sich heraus, dass die Genexpression von Kindern mit persistierenden 
Beschwerden stärker von der Genexpression gesunder Kinder abwich als die von 
Kindern, deren Symptome erst später einsetzen. 
Zusammenfassend wurden in dieser Arbeit Kandidatengene mit dem Potential eines 
prädiktiven Biomarkers für die Entwicklung von kindlichen pfeifenden/giemenden 
Atemgeräuschen identifiziert. Weitere Analysen mit dem Fokus auf die laufende 10-
Jahres-Nachbereitung sowie eine vertiefende Untersuchung der beteiligten Zelltypen 
zusammen mit der Ergebnisbestätigung in einer anderen Geburtskohorte sind notwendig 
um das Potential dieser Gene als prädiktive Biomarker vollständig zu verstehen. 
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9. ABBREVEATIONS 
CARD Caspase activation and recruitment domain 
CASP1 Casapse 1 
CBMCs Cord Blood Mononuclear Cells 
CD Cluster of differentiation 
cDNA Complementary DNA 
CI Confidence interval 
CLRs C-type lectin receptors 
CT Threshold cycle 
DAMPs Damage-associated molecular patterns 
DNA Deoxyribonucleic acid 
EDTA Ethylene diamine tetraacetic acid 
EVW Early viral wheeze  
HC Healthy controls 
IFN Interferon 
Ig Immunoglobuline 
IKK IκBα kinase complex 
IL-1R1 Interleukin 1 receptor, type I 
IQR Inter quartile range  
LMP2 Low molecular mass polypetide 5 
LMP7 Low molecular mass polypetide 7 
LOM Late onset multitrigger wheeze  
LOVW Late onset viral wheeze  
LpA Lipid A 
M Media (unstimulated) 
MDA-5 Melanoma differentiation associated gene 5 
MHC Major histocompability complex 
mRNA Messenger RNA 
MT Multitrigger wheeze 
NFκB Nuclear factor `kappa-light-chain enhancer´ of 
activated B-cells 
NLRP3 NOD-like receptor family, pyrin domain 
containing 3 
NTC Non-template control 
PAMPs Pathogen-associated molecular pattern 
PBMCs Peripheral Blood Mononuclear Cells 
PHA Phytohaemagglutinin 
PMT Persistent multitrigger wheeze  
PVW Persistent viral wheeze 
PPRs Pattern recognition receptors 
qRT PCR Quantitative real-time polymerase chain reaction 
RIG-I Retinoic acid-inducible gene I 
RLRs RIG-I like receptors 
RNA Ribonucleic acid 
TH T-helper cell 
TNF Tumor necrosis factor 
TLR Toll-like receptor 
Treg Regulatory T-cells 
VW Viral wheeze  
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12. ATTACHMENTS 
 
12.1. Declaration of consent for PAULINA and PAULCHEN 
 
EINVERSTÄNDNIS 
Zur Nabelschnurblutstudie PAULINA 
„Das Immunsystem des Neugeborenen: Charakterisierung des Phänotyps und Funktion von 
Nabelschnurblut im Rahmen von Endotoxinstimulation“ 
 
Vor und Nachname der Mutter:  ........................................ 
Name des Kindes:   ........................................ 
Anschrift:     ........................................ 
     ........................................   
Telefon:     ........................................ 
 
 
Hiermit erkläre ich/wir mein/unser Einverständnis, an der Studie teilzunehmen. Ich/Wir wurde/n 
über das Projekt und die Risiken der Teilnahme informiert. Ich/wir bin/sind damit einverstanden, 
dass bei der Mutter bei der Routineblutabnahme Blut für eine Allergietestung und aus dem 
Nabelschnurblut nach Entbindung ca. 20-30 ml Blut entnommen werden. Zudem sind wir 
einverstanden, dass für evtl. spätere Untersuchungen DNA von Mutter und Nabelschnurblut 
eingefroren wird.  
Ich/Wir kann/können diese Einverständniserklärung jederzeit ohne jegliche Folgen widerrufen.  
Das Informationsblatt habe ich/wir gelesen und ich/wir hatte/n ausreichend Zeit, diese 
Entscheidung zu überlegen. Alle meine/unsere Fragen wurden beantwortet. Eine Kopie des 
Informationsblattes und der Einverständniserklärung habe ich/wir erhalten. 
 
 
.......................................   ........................................................................ 
Ort, Datum      Unterschift der Mutter  
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EINVERSTÄNDNIS 
  
Zur Nabelschnurblutstudie PAULCHEN 
„Das Immunsystem des Neugeborenen: Charakterisierung des Phänotyps und 
Funktion von Nabelschnurblut im Rahmen von Endotoxinstimulation“ 
 
Vor und Nachname der Mutter:  ........................................ 
Name des Kindes:   ........................................ 
Anschrift:     ........................................ 
     ........................................ 
Telefon:     ........................................ 
 
 
Hiermit erkläre ich/wir mein/unser Einverständnis, an der Studie teilzunehmen. Ich/Wir wurde/n 
über das Projekt und die Risiken der Teilnahme informiert. Ich/wir bin/sind damit einverstanden, 
dass bei der Mutter bei der Routineblutabnahme Blut für eine Allergietestung und aus dem 
Nabelschnurblut nach Entbindung ca. 20-30 ml Blut entnommen werden. Zudem sind wir 
einverstanden, dass für evtl. spätere Untersuchungen DNA von Mutter und Nabelschnurblut 
eingefroren wird.  
Ich/Wir kann/können diese Einverständniserklärung jederzeit ohne jegliche Folgen widerrufen.  
Das Informationsblatt habe ich/wir gelesen und ich/wir hatte/n ausreichend Zeit, diese 
Entscheidung zu überlegen. Alle meine/unsere Fragen wurden beantwortet. Eine Kopie des 
Informationsblattes und der Einverständniserklärung habe ich/wir erhalten. 
 
 
.......................................   ........................................................................ 
Ort, Datum      Unterschrift der Mutter  
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12.2. Questionnaire for age six years follow-up for PAULINA 
and PAULCHEN 
 
For both, PAULINA and PAULCHEN age six years follow-up, similar questionnaires 
were used. The only differences in the PAULCHEN questionnaire affected questions 
regarding the home and life situations. For this reason, only the PAULINA age 6 years 
questionnaire is shown below. 
  
 
PAULINA 
 
Fragebogen zum 6. Lebensjahr 
Ihres Kindes 
 
 
 
Datum:  Studiennummer:   
 
Fragebogen für die Eltern 
Wir freuen uns, dass Sie bereit sind weiterhin an der Paulina Studie teilzunehmen. Bitte 
kreuzen Sie die folgenden Fragen an. Ihre Antworten werden vertraulich behandelt. 
Wenn Sie eine Frage nicht beantworten möchten, lassen Sie sie bitte aus. 
Wir danken Ihnen herzlich für Ihre Mitarbeit! 
Wir beginnen mit Fragen zu pfeifenden und keuchenden Atemgeräuschen. Mit pfeifenden 
Atemgeräuschen meinen wir ein pfeifendes Geräusch, das aus dem Brustkorb kommt, aber 
nicht geräuschvolles Atmen durch die Nase. 
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 Hat Ihr Kind jemals pfeifende bzw. keuchende Atemgeräusche gehabt? 
Ja  
                Falls Ja,  
                wann sind diese zum ersten Mal aufgetreten: 
Nein...      weiter mit Frage 12 
 
 Hatte Ihr Kind in den letzten 3 Jahren pfeifende bzw. keuchende Atemgeräusche? 
Ja  
Nein    weiter mit Frage 12 
 
 Wie oft hatte Ihr Kind in den letzten 12 Monaten pfeifende bzw. keuchende 
Atemgeräusche? 
Gar nicht  
1-3 mal  
4-12mal  
Mehr als 12 mal  
 
 Hatte Ihr Kind in den letzten 12 Monaten jemals Atemnot, als die pfeifenden/ 
keuchenden Atemgeräusche auftraten? 
Ja   
Nein                 
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 Wie häufig ist Ihr Kind in den letzten 12 Monaten nachts wegen pfeifender oder 
keuchender Atemgeräusche aufgewacht?  
Seltener als einmal pro Monat             
Einmal pro Monat                                    
Mindestens zweimal pro Monat             
 Wodurch wurden bei Ihrem Kind die pfeifenden / keuchenden Atemgeräusche 
ausgelöst? 
 Ja Nein 
Anstrengung   
Erkältung   
Kontakt mit Tieren   
Kontakt mit Hausstaub   
Kontakt mit Gras   
Sonstiges   
______________________________________ 
 Wie häufig hatte Ihr Kind in den letzten 12 Monaten pfeifende oder keuchende 
Atemgeräusche, ohne dass es erkältet war? 
Nie  
Seltener als einmal pro Monat  
Einmal pro Monat  
Mindestens zweimal pro Monat  
 Ist das Kind zwischen diesen Episoden völlig beschwerdefrei? 
Ja      weiter mit Frage 12 
Nein  
 Hat Ihr Kind zwischen diesen Episoden folgende Beschwerden 
 bei Anstrengung? 
 Ja Nein 
Husten   
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Pfeifende Atemgeräusche   
Atemnot   
Sonstiges:________________________________ 
Bei Temperaturwechsel/Nebel? 
 Ja Nein 
Husten   
Pfeifende Atemgeräusche   
Atemnot   
                    Sonstiges:________________________________ 
Nachts? 
 Ja Nein 
Husten   
Pfeifende Atemgeräusche   
Atemnot   
                    Sonstiges:________________________________ 
Sonstige Beschwerden? 
________________________________ 
 Hat Ihr Kind jemals in den letzten 3 Jahren von einem Arzt Medikamente gegen 
pfeifende oder keuchende Atemgeräusche, oder Giemen oder Atemnot verschrieben 
bekommen?  
(Gemeint sind damit nicht nur Medikamente zum Schlucken, sondern auch 
Inhalationen oder Sprays) 
Ja   
Nein     weiter mit Frage 12 
 Welche Medikamente waren dies?  
Bitte geben Sie den Markennamen möglichst genau an! Und sofern Sie es wissen die 
Dosis sowie den Zeitraum, in dem das Medikament eingenommen wurde. 
________________________________________ 
________________________________________ 
110 
 
 Wurde bei Ihrem Kind jemals von einem Arzt ein Allergietest durchgeführt?  
 Ja Nein 
Ein Hauttest   
Ein Bluttest   
Ein anderer Test, z.B. Bioresonanz            
 Welche Allergie wurde dabei festgestellt? 
 Ja Nein 
Gegen Pollen   
Gegen Hausstaub(milben)   
Gegen Tiere   
Gegen Nahrungsmittel   
Andere:____________________   
 Hat Ihr Kind jemals in den letzten 3 Jahren von einem Arzt Medikamente aus 
einem anderen Grund verschrieben bekommen? 
(Gemeint sind damit nicht nur Medikamente zum Schlucken, sondern auch 
Inhalationen oder Sprays) 
Ja   
Nein     weiter mit Frage 16 
 
 Welche Medikamente waren dies?  
Bitte geben Sie den Markennamen möglichst genau an! Und sofern Sie es wissen die 
Dosis sowie den Zeitraum in dem das Medikament eingenommen wurde. 
 
________________________________________ 
________________________________________ 
________________________________________ 
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Es folgen Fragen zu Beschwerden der Nase und der Augen 
 Hat Ihr Kind jemals Niesanfälle oder eine laufende, verstopfte oder juckende Nase, 
obwohl es nicht erkältet war? 
Ja  
Falls Ja, wann ist dies zum ersten Mal aufgetreten: 
 
Nein     weiter mit Frage 21 
 Hatte Ihr Kind in den letzten 3 Jahren Niesanfälle oder eine laufende, verstopfte 
oder juckende Nase, obwohl es nicht erkältet war? 
Ja  
Nein     weiter mit Frage 21 
 Hatte Ihr Kind in den letzen 12 Monaten gleichzeitig mit diesen Nasenbeschwerden 
juckende oder tränende Augen? 
Ja  
Nein  
 Wann in den letzen 12 Monaten traten diese Nasen-Beschwerden auf?  
Mehrere Antworten sind möglich. 
Januar             Mai  September  
Februar             Juni  Oktober  
März             Juli  November  
April             August  Dezember  
 Ist von einem Arzt bei Ihrem Kind schon einmal Heuschnupfen oder eine allergische 
Rhinitis bzw. Rhinokonjunktivitis festgestellt worden? 
Ja  
Nein  
Es folgen Fragen zu Hauterkrankungen 
 Hatte Ihr Kind jemals eine Neurodermitis/atopische Dermatitis/ atopisches Ekzem  
Ja   
Falls Ja, wann ist diese zum ersten Mal aufgetreten: ___________ 
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 Wurde bei Ihrem Kind die Diagnose einer Neurodermitis/atopischen Dermatitis/ 
atopisches Ekzem von einem Arzt gestellt? 
Ja  
Nein    
 Hatte Ihr Kind in den letzten 3 Jahren eine Neurodermitis/atopische Dermatitis/ 
atopisches Ekzem  
Ja   
Nein     
 War der Hautausschlag je an einer der folgenden Stellen? 
                                                Ja         Nein 
Gesicht                                  
Hals                                       
Ellenbeugen / Kniekehlen   
Hand- / Fußgelenke               
Brust/Rücken                           
 Hat sich die Lokalisation des Ausschlages im Laufe der Zeit geändert? 
Ja……………. Nein……………. 
Falls Ja, wo war er zu Beginn? Wo befindet er sich heute? 
Zu Beginn:  
                                   Ja Nein 
Gesicht                          
Hals                                      
Ellenbeugen / Kniekehlen       
Hand- / Fußgelenke              
Brust/Rücken                          
 
 
Nein     weiter mit Frage 31 
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Heute:  
                                    Ja Nein 
Gesicht                           
Hals                                       
Ellenbeugen / Kniekehlen   
Hand- / Fußgelenke               
Brust/Rücken                           
 Wenn Sie die Zeiten, in denen Ihr Kind diesen Hautausschlag hatte, 
zusammenzählen: Wie lange haben Sie diesen Hautausschlag insgesamt beobachtet? 
Für insgesamt weniger als 3 Monate   
Für insgesamt 3-6 Monate    
Für insgesamt 6-12 Monate    
Für länger als 12 Monate     
 Ist der Hautausschlag wieder völlig verschwunden, oder „kommt und geht“ der 
Hautausschlag? 
Der Hautausschlag ist vollständig  
Verschwunden                           
Der Hautausschlag „kommt und geht“   
Der Hautausschlag ist noch da    
 Wie alt war Ihr Kind, als der Hautausschlag vollständig verschwunden ist?  
 ______ Monate 
 Wie häufig ist Ihr Kind nachts wegen Juckreiz aufgewacht? 
Seltener als einmal pro Monat oder nie  
Einmal pro Monat  
Mindestens zweimal pro Monat  
 Haben Sie die Haut Ihres Kindes in den letzten 12 Monaten mit einer 
cortisonhaltigen Creme / Salbe oder einer Tacrolimus- bzw. Pimecrolimus-haltigen 
Salbe (Protopic, Elidel) behandelt? 
Ja  
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Nein  
32. Wie äußert sich diese Nahrungsmittelallergie? 
Ausschlag/rote Flecken um den Mund herum  
Ausschlag/rote Flecken an anderen Körperstellen  
Schwellung der Lippen    
Juckreiz    
Durchfall   
Erbrechen  
Verschlechterung der Neurodermitis  
Pfeifende Atemgeräusche   
Atemnot   
Kreislaufreaktion/Blutdruckabfall  
Sonstiges:                                                                  
33.  Auf welche Nahrungsmittel reagiert Ihr Kind? 
                                                                     Ja Nein 
Milch und Milchprodukte                                      
Hühnereier                                                              
Fisch                                                                          
Weizenmehl oder andere Getreideprodukte   
Nüsse                                                                          
Soja                                                                          
Zitrusfrüchte                                                              
Anderes Obst oder Gemüse                                       
Es folgen Fragen zu Nahrungsunverträglichkeiten oder –allergien 
 Hat Ihr Kind eine Nahrungsmittelallergie? 
                                     Ja  
                                     Nein    weiter mit Frage 34 
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Andere Nahrungsmittel                                        
Welche? ____________________________ 
Es folgen Fragen zu anderen Erkrankungen 
34. Wurde bei Ihrem Kind jemals von einem Arzt/einer Ärztin eine spastische 
Bronchitis, obstruktive Bronchitis oder asthmatische Bronchitis diagnostiziert? 
Nein, nie   
Ja, einmal   
Ja, mehrmals   
35.  Wurde bei Ihrem Kind in den letzten 12 Monaten von einem Arzt/einer Ärztin eine 
der folgenden Diagnosen gestellt? 
                                    Ja  Nein 
Asthma                            
Neurodermitis, atopische Dermatitis    
oder endogenes Ekzem     
Allergische Rhinitis/Heuschnupfen     
36. Hatte Ihr Kind bisher eine der folgenden Erkrankungen nach dem dritten 
Lebensjahr? 
                         Ja Nein 
Mittelohrentzündung   
Pseudokrupp    
Lungenentzündung   
Bronchitis               
Bronchiolitis               
Keuchhusten               
Andere Infektionen   
Welche? __________________________________________  
Waren stationäre Aufenthalte im Krankenhaus notwendig   
Warum? __________________________________________ 
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Angaben zur Wohnungs- und Lebenssituation 
37. A) Wie viele jüngere Geschwister hat Ihr Kind? 
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben! 
Schwestern....................... Brüder...............................  
B) Wie viele ältere Geschwister hat Ihr Kind? 
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben! 
Schwestern.......................Brüder............................... 
 
38. Bitte notieren Sie Name und Geburtsdatum der Geschwister Ihres Kindes.  
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben! 
 
 Name Mädchen Junge Geburtsdatum 
_____________          ___/___/_____ 
____________   ___/___/_____ 
 ____________   ___/___/_____ 
39. Wird Ihr Kind regelmäßig zusammen mit anderen Kindern durch eine Tagesmutter 
oder bei den Großeltern betreut? Die eigenen Geschwister sind dabei nicht gemeint. 
Ja,  
Mit wie vielen anderen Kindern: _____ 
Nein  
40. Wird Ihr Kind regelmäßig zusammen mit anderen Kindern in einer Kinderkrippe 
oder im Kindergarten betreut? Die eigenen Geschwister sind dabei nicht gemeint. 
Ja,  
Mit wie vielen anderen Kindern? _____ 
Nein  
  
117 
 
41. Welche der folgenden Haustiere haben/hatten Sie innerhalb der Wohnung? Mehrere 
Antworten sind möglich. 
Keine   
Hund  
Katze   
Hamster  
Meerschweinchen  
Kaninchen  
Vögel  
Aquarium (Fische)  
Sonstige  
 
Welche: __________________________________________________________________ 
A) Darf oder durfte sich eine Katze im Zimmer, in dem Ihr Kind schläft aufhalten? 
Ja  
Nein  
B) Darf oder durfte sich eine Katze im Bett Ihres Kindes aufhalten?  
Ja  
Nein  
C) Darf oder durfte sich ein Hund im Zimmer, in dem Ihr Kind schläft aufhalten? 
Ja  
Nein  
D) Darf oder durfte sich ein Hund im Bett Ihres Kindes aufhalten?  
Ja  
Nein  
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42. Hat Ihr Kind sonst regelmäßig (ca. 1x/Woche) Kontakt zu Tieren (z.B. in der 
Wohnung von Freunden/ Verwandten)? Mehrere Antworten sind möglich. 
             Ja                            Nein 
Hund        
Katze         
Sonstige                
Welche:______________________________________________________ 
43. Gibt es in Ihrer Wohnung Feuchtigkeitsflecken bzw. Schimmelbefall an Wänden 
oder Decken? 
Feuchtigkeitsflecken in Bad oder Küche sind dabei nicht gemeint, sondern nur in 
Räumen wie Wohnzimmer, Schlafzimmer oder Kinderzimmer. 
                                                                    Ja Nein 
Feuchtigkeitsflecken, aber ohne Schimmelbefall    
                                                                      Ja Nein 
Feuchtigkeitsflecken mit Schimmelbefall   
 
Es folgen Fragen zum Rauchverhalten 
44. Rauchen Sie oder Ihre Familie in Ihrer Wohnung/Haus? 
Ja  
Nein    
 
45. Haben Sie und Ihre Familie in den letzten 12 Monaten mit dem Rauchen in der 
Wohnung aufgehört bzw. das Rauchen innerhalb der Wohnräume 
eingeschränkt?  
Ja  
Nein    
Es wurde nie geraucht   
46. Wie viele Zigaretten werden durchschnittlich am Tag in Ihrer Wohnung (damit 
meinen wir auch die Küche) geraucht? Zigaretten, die auf dem Balkon oder der 
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Terrasse geraucht werden, brauchen nicht mitgezählt zu werden. Wie viele davon 
von...  (keine=0) 
Mutter _____ pro Tag 
Partner _____ pro Tag 
Andere Personen _____ pro Tag 
Insgesamt _____ pro Tag 
 
Haben Sie noch weitere Kommentare zum Fragebogen oder allgemein? 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______ 
 
 
Wir danken Ihnen herzlich für das  
Ausfüllen des Fragebogens! 
 
Bei Fragen können Sie sich jederzeit gerne an uns wenden.  
Studienleitung:        
PD Dr. med. Bianca Schaub, i.A. Fr. Isolde Schleich 
Dr. von Haunersches Kinderspital 
Lindwurmstr. 4 
80337 München 
Tel: 089/ 5160-7781 
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12.3. Stratification for maternal school years 
 
As maternal education was revealed as a possible confounder (see Table 9), gene 
correlation of gene expression and maternal school years was analyzed. For LMP2, LMP7 
and NLRP3, there were significant findings after PHA stimulation. In a second step, the 
found findings within these genes were analyzed stratified for maternal school years.  
Table 50: analysis of affected findings stratified for maternal school years 
  Trends and significant findings  Stratified for school years 
 
years  
LMP2 after PHA 
stimulation 
MT > HC  p-value= 0.056 9 --- 
10 MT > HC  p-value= 0.19 
13 MT > HC  p-value= 0.095 
16 MT < HC  p-value= 0.8 
LMP7 after PHA 
stimulation 
MT > EVW  p-value= 0.084 9 --- 
10 MT > EVW  p-value= 0.4 
13 MT > EVW  p-value= 0.33 
16 MT < EVW  p-value= 0.97 
NLRP3 after PHA 
stimulation 
MT > VW  p-value= 0.005 
MT > EVW  p-value= 0.013 
MT > HC  p-value= 0.015 
9 MT > VW  p-value= 0.67 
--- 
--- 
10 MT > VW  p-value= 0.4 
MT > EVW  p-value = 1.0 
MT > HC  p-value = 0.19 
13 MT > VW  p-value= 0.33 
MT > EVW  p-value = 0.67 
MT > HC  p-value = 0.57 
16 MT > VW  p-value= 0.17  
MT > EVW  p-value = 0.31 
MT > HC  p-value = 0.37 
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Table 51: analysis of affected findings in the more detailed phenotype subgroups stratified for maternal school years 
  Trends and significant findings  Stratified for school years 
 
years  
LMP2 after PHA 
stimulation 
PMT > HC  p-value= 0.0016 
PMT > EVW  p-value= 0.033 
PMT > LOVW  p-value= 0.063 
9 --- 
10 PMT > HC  p-value= 0.19 
PMT < EVW  p-value= 1.0 
13 --- 
16 PMT > HC  p-value= 0.12 
PMT > EVW  p-value= 0.08 
PMT > LOVW  p-value= 0.27 
NLRP3 after PHA 
stimulation 
PMT> HC  p-value= 0.052 
PMT> EVW  p-value= 0.024 
PMT> PVW  p-value= 0.058 
PMT> LOVW  p-value= 0.057 
 
 
9 --- 
10 PMT > HC  p-value= 0.57 
PMT < EVW  p-value= 0.67 
--- 
13 ---- 
16 PMT > HC  p-value= 0.052 
PMT > EVW  p-value= 0.017 
PMT > PVW  p-value= 0.19 
PMT > LOVW  p-value= 0.13 
NLRP3 after PHA 
stimulation 
LOM > HC  p-value= 0.063 
LOM > EVW  p-value= 0.066 
LOM > PVW  p-value= 0.072 
LOM > LOVW  p-value= 0.036 
9 --- 
 
10 LOM > HC  p-value= 0.19 
LOM > EVW  p-value= 0.67 
LOM > PVW  p-value= 0.67 
LOM > LOVW  p-value= 0.67 
13 LOM > HC  p-value= 0.57 
LOM > EVW  p-value= 0.67 
LOM > PVW  p-value= 0.33 
LOM > LOVW  p-value= 0.67 
16 LOM < HC  p-value= 0.96 
LOM < EVW  p-value= 0.95 
LOM < PVW  p-value= 0.78 
LOM < LOVW  p-value= 0.96 
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